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Background. Ticks are blood feeding arachnids that characteristically take a long blood meal. They must therefore counteract
host defence mechanisms such as hemostasis, inflammation and the immune response. This is achieved by expressing
batteries of salivary proteins coded by multigene families. Methodology/Principal Findings. We report the in-depth analysis
of a tick multigene family and describe five new anticomplement proteins in Ixodes ricinus. Compared to previously described
Ixodes anticomplement proteins, these segregated into a new phylogenetic group or subfamily. These proteins have a novel
action mechanism as they specifically bind to properdin, leading to the inhibition of C3 convertase and the alternative
complement pathway. An excess of non-synonymous over synonymous changes indicated that coding sequences had
undergone diversifying selection. Diversification was not associated with structural, biochemical or functional diversity,
adaptation to host species or stage specificity but rather to differences in antigenicity. Conclusions/Significance.
Anticomplement proteins from I. ricinus are the first inhibitors that specifically target a positive regulator of complement,
properdin. They may provide new tools for the investigation of role of properdin in physiological and pathophysiological
mechanisms. They may also be useful in disorders affecting the alternative complement pathway. Looking for and detecting
the different selection pressures involved will help in understanding the evolution of multigene families and hematophagy in
arthropods.
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INTRODUCTION
Parasites probably affect every living organism and it may
reasonably be estimated that at least half the animals on earth
are parasites [1]. By definition, parasites live at the expense of their
host but hosts defend themselves and, in turn, parasites evolve
counter-measures. Parasitism is probably therefore a major driving
force in evolution [1]. Bloodfeeding arthropods such as ticks
constitute a very good example of the evolutionary arms race
between hosts and parasites.
Ticks are obligate blood feeding arachnids. They infest many
species of mammals, birds, reptiles and amphibians worldwide.
They are the vectors of protozoan, bacterial and viral pathogens of
prime medical and veterinary importance. Examples of such
important pathogens are Borrelia burgdorferi, Tick-borne Encepha-
litis Virus (TBEV), Babesia bovis or Theileria parva, the respective
agents of Lyme disease and viral encephalitis in humans, and
babesiosis and theileriosis (East Coast Fever) in cattle [2]. Blood
losses due to heavy infestation may weaken the animal, render it
more susceptible to other diseases or cause death by exsanguina-
tion [3]. In addition, the occurrence of tick toxicosis including tick
paralysis is associated with the presence of toxins in the saliva [4].
There are two main families of ticks, Ixodidae or hard ticks and
Argasidae or soft ticks. The Ixodidae family is further divided into two
subdivisions: Prostriata, which contains only the subfamily Ixodinae,
and Metastriata, which includes the subfamilies Bothriocrotinae,
Amblyomminae, Haemaphysalinae and Rhipicephalinae [3]. Argasid ticks
typically feed for short periods of time (up to 2 hours) whereas
Ixodid ticks remain attached to and feed on their vertebrate host
for up to two weeks [3]. The feeding time of an adult Ixodes ricinus
female is typically 7–10 days [3]. Such a long blood meal is only
possible because these parasites have developed ways to circum-
vent host defense mechanisms including hemostasis (coagulation,
platelet aggregation and vasoconstriction), the inflammatory
response and innate and adaptive immunity [reviewed in
5,6,7,8]. Furthermore, pain or itching caused by the inflammatory
response stimulates hosts to scratch and dislodge the parasite.
The complement system is a first line of defence against invading
pathogens and it links the innate and adaptive responses of the
vertebrate immune system [reviewed in 9]. It consists of a cascade of
plasma enzymes leading to activation of three effector mechanisms:
(i) generation of the short potent pro-inflammatory peptides C3a and
C5a, ii) deposition of opsonizing C3b proteins on cell surfaces, (iii)
formation of the membrane attack complex (MAC). MACs create
pores in the membrane, leading to cell death. Complement is
activated via three main pathways. The classical pathway (CP) is
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initiated mainly when the C1 complex binds to the Fc region of
certain antibody isotypes in immune complexes. The lectin-
mediated pathway is activated by mannose-binding lectin interacting
with mannose residues on microbial surfaces.
The alternative pathway (AP) is spontaneously activated by
hydrolysis of plasma C3 into C3 (H2O). C3 (H2O) binds soluble
factor B (fB). Bound fB is cleaved by serine protease factor D into
soluble Ba peptide and the larger Bb fragment. The resulting C3
(H2O)Bb complex is the initial C3 convertase. It cleaves fluid-
phase C3 into C3a peptide and metastable C3b. C3b binds
covalently to a pathogen or cell surface via a short-lived thioester
bond. Factor B interacts with C3b, leading to its cleavage by factor
D and the formation of the C3 convertase (C3bBb). This complex
generates new C3b molecules and amplifies the complement
cascade by forming new C3 convertases or C5 convertases
(C3b2Bb). C5 convertase cleaves C5 into C5a and C5b. C5b
initiates the formation of MAC [9].
Host cells are protected from attack by the complement system
by plasma and membrane-bound regulatory molecules that
inactivate complement proteins. C3 convertases are deactivated
by dissociation mediated by surface proteins such as Decay-
Accelerating Factor (DAF) and Complement Receptor-1 (CR1), as
well as soluble factor H. These proteins bind to C3b and displace
Bb [9]. They also act as co-factors for serine protease factor I
which cleaves C3b [10]. On the other hand, the half-life of C3
convertase is increased at least 10-fold by properdin [11]. It is
present in the plasma in oligomer form (dimer, trimer or tetramer)
[12,13]. Each monomer is a 53 kDa protein composed of six
repetitive thrombospondin domains (TSP), flanked with an N-
terminal and C-terminal region [14,15,16]. Properdin binds to
surface-bound C3b and increases its ability to interact with factor
B [17]. It also binds to pre-formed C3 convertases leading to
increased stability and preventing inactivation by regulators such
as factor H and factor I [9]. Moreover, properdin oligomers
attached to C3b on cell surfaces interact with preformed fluid-
phase C3b or C3bBb through its other subunits [18]. The essential
role of properdin in complement activation was demonstrated by
the capacity of an anti-properdin monoclonal antibody to inhibit
activation of the alternative pathway. This monoclonal antibody
prevents the interaction between properdin and C3b [19].
The AP is the major line of defense against invading pathogens
such as bacteria [20]. It is also involved in guinea pig resistance to
the hard tick Dermacentor andersoni [21,22]. Saliva or salivary gland
extracts from Ixodes dammini [23], I. hexagonus and I. uriae [24], I.
scapularis [25] and I. ricinus [24,26] have been found to have an
inhibitory activity on the alternative complement pathway.
Valenzuela et al. [25] purified the active anticomplement
component from the saliva of adult I. scapularis. N-terminal
sequencing combined with the screening of a cDNA library led to
the description of the coding sequence of a tick anticomplement
protein named ISAC (I. scapularis anti-complement). Recombinant
ISAC mimics the anticomplement activity of tick saliva. It
interferes with the formation of C3 convertase from C3 and fB
and destabilizes pre-formed C3 convertase. Sequences closely
related to ISAC were then cloned by RT/PCR from I. scapularis
nymphs [27], found by screening a cDNA library with sera from
repeatedly infested guinea pigs [28] or by PCR-screening of a
nymph cDNA library [29]. In I. pacificus, sequencing large
numbers of cDNA clones from adult salivary glands led to the
discovery of ISAC-I [30]. Finally, using degenerate primers
designed from the published ISAC sequence, Daix et al. [31]
recently cloned the related IRAC I and IRAC II from I. ricinus.
In soft ticks too, anticomplement activity is present in saliva and
salivary gland extracts [32]. In Ornithodoros moubata, this activity is
due to protein OmCI which inhibits both the alternative and
classical pathways. Its sequence is unrelated to the Ixodes
anticomplement molecules mentioned above (,15% amino-acid
identity). OmCI binds to C5 component of the complement
cascade and belongs to the lipocalin superfamily [33].
The recent characterization of large numbers of cDNA sequences
from salivary glands of Ixodid ticks including I. scapularis [34,35] and
I. pacificus [30] indicated that most salivary proteins are expressed as
large clusters of related proteins, probably coded by multigene
families. Moreover, genome size and organization were examined in
Ixodes scapularis, Boophilus microplus [36] and Amblyomma americanum
[37]. These genomes are large: 2.16109, 7.16109 bp and 1.046109
bp respectively. Reassociation rates of genomic DNA indicate that
they are composed mainly of moderately repetitive elements, which
include transposable elements and members of multigene families.
This organization in multigene families is therefore probably a major
feature of hard tick genome organization and perhaps an adaptation
to bloodfeeding.
In the work described here we completed an inventory of
sequences related to I. scapularis anticomplement protein ISAC in the
salivary glands of I. ricinus. We were able to detect five new sequences
that we used to study diversification mechanisms possibly at work in
a family of tick salivary proteins (hereby referred to as the IxAC
family) and we investigated their action mechanism. The results
showed that I. ricinus anticomplement proteins specifically bind to
properdin, leading to the inhibition of the formation of C3
convertase and inhibition of the alternative complement activation
pathway. Sequence diversification is associated with antigenic
diversity rather than major divergence in molecular characteristics
or activity, host specificity or stage specificity.
In this study, we investigated the general significance of
multigene families in the context of a host-parasite relationship.
This is a specific in-depth analysis of a tick multigene family. It
highlights the value of performing dedicated gene-targeted
inventories when studying specific aspects of tick adaptation to a
bloodfeeding lifestyle. Remarkably, IxACs from I. ricinus are also
the first inhibitors that specifically target a positive regulator of
complement.
RESULTS
A large family of anticomplement proteins in the
hard tick Ixodes ricinus
The fragments of two genes related to the prototypical Ixodes
scapularis anticomplement protein ISAC of Valenzuela et al. [25]
were found by serendipity in cDNA from pooled salivary glands.
The complete coding sequences as well as parts of the 39 and 59
UTR’s were then reconstituted by RACE. The new genes
(accession numbers: AM407396 and AM407397) coded for two
new proteins showing ,40 % identity with ISAC and the recently
described IRAC I and IRAC II from I. ricinus [31], but over 65 %
identity with each other. This led us to suspect the existence of a
much larger family of anticomplement proteins in I. ricinus.
In order to make as complete an inventory of this family as
possible, a total of 2 different reverse transcription experiments, 6
different PCR amplifications and 12 ligations were performed on
polyA+ RNA from salivary glands of I. ricinus females (Table S1).
122 clones with inserts of the expected size ($600 bp) were
sequenced. A few were disregarded as they coded for proteins
unrelated to anticomplement proteins (e.g. ribosomal proteins). A
few additional clones with inserts smaller than expected (400–
500 bp) were sequenced too. They were found to code for
homologs of uncharacterized ‘‘putative salivary proteins’’ from I.
scapularis and I. pacificus. Of the 118 anticomplement-like clones
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found, most could be assigned to previously described IRAC I,
IRAC II, AM407396 and AM407397 on the basis of sequence
identity. AM407396 was the most frequent (46.6 %) followed by
AM407397 (23.3 %), IRAC I (15.5 %) and IRAC II (0.9%). Three
additional new sequences were also identified. They were assigned
accession numbers AM407398, AM407399 and AM407400
respectively. They accounted for 3.4 %, 8.6 % and 1.7% of
clones, respectively. Sequences found to be identical in $3
independent clones were considered genuine. AM407400 was only
represented by two clones which showed a difference of two
nucleotides. Therefore, the latter sequence was confirmed
independently by amplifying internal fragments with gene-specific
primers from salivary gland cDNA. Finally, the same set of
sequences was found from the various independent RT-PCR
experiments (Table S1). Overall, the results suggested that a
complete or near-complete inventory of IxAC anticomplement
messengers from the Ixodes ricinus salivary gland was achieved at
least for the population investigated.
PCR experiments using the primers listed in Table 1 were also
performed on cDNA from pooled salivary glands of 3 day-fed male
and female R. appendiculatus. No PCR products were observed (not
shown). We were nevertheless able to amplify the coding sequence
for the known lipocalin RaHBP-2 from the same cDNAs using
specific primers. Interrogation of databases including the prelim-
inary releases of sequences from the non-Ixodes hard tick R.
appendiculatus, B. microplus, A. americanum and A. variegatum genome
projects yielded no or only insignificant hits.
Phylogenetic analysis of tick anticomplement
sequences
Nucleotide and peptide sequences of ISAC, IRAC I and AM407396
were used to interrogate databases with the same results. A total of 48
entries were recovered (Table S2). These were from I. scapularis (45
entries), I. ricinus (2 entries) and I. pacificus (1 entry). They had been
cloned from salivary glands (30), whole fed nymphs and nymph
salivary glands (15) or unspecified tick material (3).
Two sequences containing ambiguous positions and ten
sequences with incomplete coding sequences for the mature
protein, including Salp9 (AF278574) and Isac-like clone 113
(AY956386), were initially discarded. These 12 entries were from
I. scapularis. The remaining 36 entries were aligned with our five
new sequences from I. ricinus (AM407396 to AM407400). Distance
dendrograms were constructed from alignments of nucleotide
sequences or predicted amino-acid sequences of putative mature
proteins translated from the open reading frames (Figure 1). All
sequences clustered into two main groups or subfamilies, IxAC-A
and IxAC-B, which were strongly supported by bootstrap analysis
(1000/1000). IxAC-A could be further divided into two clusters. A
first, large, group contained only I. scapularis sequences closely related
to prototypical ISAC. It was strongly supported by bootstrap analysis
(.900/1000). A second, smaller, cluster contained Isac-1 from I.
pacificus, IRAC II from I. ricinus, Salp20-like protein 2 and EST nu
DN970085 from I. scapularis. Bootstrap support was lower ($830/
1000). IRAC I could not be joined robustly (bootstrap value ,750/
1000) to any of the previous two clusters. The IxAC-B subfamily
contained our five new sequences AM407396 to AM407400 from I.
ricinus but none from other tick species. No robust cluster emerged
within this subfamily.
The maximum-likelihood method was also applied to the initial
nucleotide and amino-acid alignment of putative mature proteins. It
supported the same topology as the distance method with slightly
different bootstrap values (Figure 1). The two subfamilies were
strongly supported (1000/1000). The two clusters within IxAC-A
were also recovered but bootstrap support was lower than with the
distance method. Again, IRAC I could not be placed robustly in any
of the two clusters within IxAC-A (bootstrap support ,650/1000).
The overall topology of the distance trees was not altered after
including the leader peptide sequences in the alignments (not shown)
or the 12 discarded sequences (not shown). Most of the latter
clustered with ISAC within the ISAC-like cluster (not shown). Only
Salp9 grouped with Isac-I, IRAC II and EST nu DN970085 within
the second cluster in IxAC-A. Salp9, a 79 residues peptide, aligned to
the C-terminal half of DN970085 to which it showed 90% identity.
Because ISAC and Salp9 were the earliest tick anticomplement
sequences published, we decided to name the large and small clusters
within IxAC-A ‘‘ISAC-like’’ and ‘‘Salp9-like’’, respectively.
We therefore decided to rename the five new sequences
(AM407396 to AM407400) IxAC-B1 to IxAC-B5 to indicate the
fact that they clustered into the new group or subfamily IxAC-B
and away from the previously described IRAC I and IRAC II
which belong to the IxAC-A subfamily.
Table 1. PCR primers for RT-PCR inventory of I. ricinus genes coding for anticomplement proteins.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primer sequence Tm (uC) Designed from Usage
IRI (fw) 59-ACCATGARGACTGYGCTGACCTGTGC –39 70–74uc 59 end of I. ricinus anticomplement CDS Inventory in adult SG
IXO (fw) 59-ACCATGARGACTGYGYTBACCTGTGC –39 66–74uc 59 end of Ixodes spp. anticomplement CDS
Not1 primer (rev) 59-AGAATTCGCGGCCGCAGGAAT -39 66uc 39 race primer for Not1Oligod(T)18 RT primer
Generacer 39 59–GCTGTCAACGATACGCTACGTAACG-39 76uc 39 race primer for Generacer Oligo dT primer
UTR1 (rev) 59-CACCACGCAGTGCCATCTGT–39 64uc 39 UTR of IxAC-B1 to B5
UTR2 (rev) 59–ATGGGTATCGGCATACCGATC-39 64uc 39 UTR of IxAC-B1 to B7
UTR3 (rev) 59–GTTTCTGGTAATAACCGGGTG–39 62uc 39 UTR of IRAC-I and IRAC-II Inventory in nymphs
and larvae
UTR4 (rev) 59–CGYATCAGAACTRTGCTTGCAC–39 64–68uc 39 UTR of Isac-like
CDSrev1 (rev) 59–TCAKGSGATGGCCTCARGTTC–39 64–68uc C-terminal end of IRACI and II CDS
CDSrev2 (rev) 59–YTYRRASRGGGTGGTCGG–39 54–64uc C-terminal end of IxAC-B1 to B5 CDS
Forward primers IRI and IXO were designed manually from the 59 end of coding sequences of anticomplement proteins available at the start of this project from I.
ricinus and Ixodes spp. respectively. The trinucleotide ACC was added 59to the start codon to improve eukaryotic expression. Commercial reverse primers Generacer 39
and Not1 are available from Invitrogen and Amersham Biosciences, respectively. Family-specific reverse primers were designed from UTR or coding sequences of the
different subfamilies of tick anticomplement proteins as indicated. Calculated mean melting temperatures (Tm) are also indicated. CDS, coding sequences; UTR,
untranslated region; SG, salivary gland.
doi:10.1371/journal.pone.0001400.t001..
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Percentages of identity and similarity were calculated for
representative IxACs (Table 2). Within a subfamily, amino-acid
sequences were over 60 % identical whereas identity dropped to
,40 % between the two subfamilies. The two subfamilies could
also be differentiated by an indel of 4 amino-acids (position 74 to
77 in Figure 2). Within the Isac-like cluster or within the Salp9-like
cluster, amino-acid sequences were at least 70% identical.
According to information provided on the entry files or in the
original publications, the sequences had been obtained from adults
(12), nymphs (34) or unspecified stages (2). However, no robust
‘‘adult-only’’ or ‘‘nymph-only’’ clusters could be discerned
(Figure 1). Moreover, ‘‘adult’’ EST nu DN968378 was found to
be 100% identical to ‘‘nymphal’’ Salp20 (AF209917) (Figure 1).
To summarize, phylogenetic analysis of all available tick
anticomplement sequences indicated that they robustly segregated
into two distinct groups or subfamilies, which we termed IxAC-A
and IxAC-B. Within-group amino-acid identity was .60%
whereas between-group identity dropped to ,40%. The larger
IxAC-A contained sequences from I. scapularis, I. ricinus and I.
pacificus. It could be subdivided into two or possibly three clusters.
Our new sequences from I. ricinus constituted a completely new
group which we named IxAC-B. No stage-specific group of
sequences was identified at this point of the research.
Protein properties
The properties of these newly discovered proteins were predicted
from their amino-acid sequences and compared to prototypical
ISAC from I. scapularis and related Isac-1 from I. pacificus.
Calculated PM and pI ranged from 17.46 to 18.03 and 4.01 to
4.29 respectively (Table 3).
All anticomplement proteins presented four conserved cysteine
residues predicted to make two disulphide bridges (Figure 2).
Most likely signal peptide cleavage sites for representative IxACs
are indicated in Table 3 and Figure 2. In each individual peptide
sequence, SignalP predicted a second or even a third probable,
Figure 1. Phylogenetic analysis of Ixodes anticomplement proteins. A distance dendrogram was constructed from an alignment of 41 tick mature
anticomplement proteins using programs in the Phylip 3.65 package (see text). Branch length is proportional to distances between peptide
sequences. The bootstrap values are indicated near major nodes, calculated from 1000 replicates of the peptide and nucleotide sequence alignments,
respectively. Bold characters: I. ricinus entries; *: I. pacificus sequence; all others are from I. scapularis. Prototypical ISAC is boxed. Sequences are
identified by their accession number in databases or by descriptive names when available. Ad., isolated from adults; Ny., isolated from nymphs; NS,
not specified.
doi:10.1371/journal.pone.0001400.g001
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though less likely, cleavage site. These were at position 19 (after C
residue), 21 (after SS residues) or 22 (after SSN/E). Altogether,
cleavage at any 3 locations within the CqSSq(S)qE/N motif is
theoretically possible.
The presence of a signal peptide and the absence of any
hydrophobic transmembrane region suggests that these proteins are
secreted. This was supported by a TargetP program analysis and
confirmed experimentally as recombinant IxACs were recovered in
the culture medium after transfection of COS7 or 293T cells.
In a western blot analysis using an anti-V5 antibody, all
recombinant IxACs from I. ricinus appeared as a series of thin
bands at 50–70 kDa (Figure 3a). The apparent molecular weights
are consistent with reported values for purified native anticom-
plement proteins from I. scapularis (,65 kDa) [25] and I. damini
(,49 kDa) [23]. They contrast with the predicted MW of
,18 kDa. This difference and the appearance of the bands were
in agreement with extensive glycosylation. Indeed, several
consensus sites for N- and O- glycosylation were found in the
sequences (Table 3). Furthermore, the presence of N-linked
glycosylation was experimentally confirmed by treatment with N-
glycosidase F leading to a fall in observed MW to 35–45 kDa
(Figure 3b). Recombinant Salp20 expressed in insect cells also
appears as a smear possibly representing differentially glycosylated
forms of the protein [29]. The authors experimentally confirmed
the presence of N-linked and O-linked sugars.
Finally, hydrophobic cluster analysis (HCA) showed that the
distribution of clusters of hydrophobic amino-acids had a nearly
identical distribution in all 7 IxACs from I. ricinus as well as in
ISAC and ISAC-1 (Figure 4). This suggested that these 9 proteins
had identical folds or tertiary structures.
The excess of non-synonymous over synonymous
changes indicates that the coding sequences had
undergone diversifying selection
Calculation of the percentage identity between 7 I. ricinus
anticomplement sequences indicated that they were more closely
related at the nucleotide level than at the amino-acid level (Table 2).
A theoretical ancestral sequence was also re-constructed using the
Ancescon program. It was aligned to the 7 actual sequences. The
numbers of synonymous changes per synonymous sites (dS) and non-
synonymous changes per non-synonymous sites (dN) were calculated
using the Nei-Gojobori method. Values for dN/dS were consistently
.1 for pairwise comparisons of actual sequences with one another
and with the putative ancestral sequence (Table 4, higher-right
triangle). The ratio from overall means of dN and dS values was
2.44. Fisher’s exact test for positive selection did not reject the
hypothesis of dN .dS except in the case of IRAC I compared to
IRAC II (P value ,0.05) (Table 4, lower left triangle).
All the data therefore show that diversifying selection had taken
place within the IxAC family in I. ricinus.
Table 2. Nucleotide and amino-acid identity/similarity of
mature anticomplement proteins.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Isac Isac-1 IRAC I IRAC II
IxAC-
B1
IxAC-
B2
IxAC-
B3
IxAC-
B4
IxAC-
B5
Isac 61/76 63/75 62/77 37/53 39/55 38/52 36/51 40/54
Isac-1 76 62/74 78/90 40/57 44/58 40/55 37/55 40/58
IRAC I 78 79 61/74 35/52 38/53 37/52 37/50 36/52
IRAC II 76 91 78 37/57 41/58 37/55 37/57 41/58
IxAC-B1 51 54 51 53 66/77 68/81 64/78 75/82
IxAC-B2 51 55 50 53 79 63/76 66/77 73/83
IxAC-B3 51 54 51 53 81 79 63/76 65/76
IxAC-B4 49 53 49 52 78 79 77 68/76
IxAC-B5 52 54 50 53 86 82 80 81
Percent identity/similarity of amino acid sequences are indicated in the upper
right triangle. Percent identities of nucleotide sequences are indicated in the
lower left triangle.
doi:10.1371/journal.pone.0001400.t002..
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Figure 2. Alignment of Ixodes anticomplement proteins. The 7 anticomplement proteins from I. ricinus (IRAC I and II; IxAC-B1 to B5) were aligned
with the prototypical anticomplement protein from I. scapularis (ISAC) and the homolog from I. pacificus (ISAC I). Individual residues printed in white
on a black background are conserved in all 9 aligned sequences; white residues on a grey background are conserved in 7 or 8 of 9 entries; black
residues on a grey background are conserved in 5 or 6 entries; black residues on a white background are conserved in less than 5 entries. -, gap; ! !,
region of predicted signal peptide cleavage; C1 to C4, conserved cysteine residues.
doi:10.1371/journal.pone.0001400.g002
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IxACs from I. ricinus inhibit the alternative
complement pathway (AP) but not the classical
pathway (CP)
The effect of similar amounts of the seven I. ricinus IxACs
transiently expressed in 293T cells (Figure 3) were assessed in
hemolytic assays of both the classical (CP) and alternative
complement pathways (AP). A clear dose-dependent inhibition
of the AP was observed for all seven recombinant proteins tested
as they inhibited the lysis of rabbit erythrocytes by normal
human serum. The shape of the curves and plateau values
for hemolysis inhibition were identical for the seven proteins
(Figure 5).
Addition of recombinant IxACs in the AP assay 15 minutes
after adding red blood cells to human serum in the AP assay
showed that they were able to inhibit ongoing hemolysis of rabbit
erythrocytes. (Figure S1).
The same dilutions of the 7 recombinant proteins were retested
in the CP assay in the presence of normal human serum. As shown
in Figure 5, there was no inhibition of lysis of antibody-sensitized
sheep erythrocytes.
In both assays, no inhibition was observed after addition of
recombinant RaHBP2.
We therefore concluded that the 7 IxAC from I. ricinus all had a
similar inhibitory effect on the alternative but not the classical
complement activation pathway.
IxACs inhibit the cleavage of human C3 and factor B
During complement activation by the alternative pathway, plasma
protein C3 is cleaved into the large opsonizing factor C3b and the
small pro-inflammatory peptide C3a and precursor B is cleaved
into a large Bb fragment and a small Ba peptide. We investigated
the effect of I. ricinus IxAC proteins on the cleavage of factor B and
on the production of C3a in the AP assay. Supernatants of
completed AP hemolytic assays were analyzed by Western blot
using antisera to fB or C3a.
As shown in Figure 6A, anti-C3a antibody recognized major
bands at 116 kDa, 77kDa and ,10 kDa. Arrows indicate clearly
identifiable bands; they corresponded to the a-chain of C3
(115 kDa) and the small C3a peptide (9 kDa) [38,39]. The
latter was almost completely suppressed in samples from assays run
in the presence of recombinant IxACs as compared to sample
Table 3. Calculated properties of anticomplement proteins.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sequence name Accession number Precursor size (aa) Signal peptide cleavage site Maturec MW (kDa) Maturec pI N-gly. O-gly.
Most likely Less likely
ISACa AAF81253.1 184 21–22 22–23 18.14 4.19 6 12
Isac-1b AAT92205.1 178 22–23 21–22 17.55 3.99 5 15
IRAC I CAD82867 184 19–20 22–23 18.03 4.01 5 8
IRAC II CAD82868 178 21–22 22–23 17.46 4.29 5 12
IxAC-B1 AM407396 177 21–22 19–20, 20–21 17.58 4.00 6 12
IxAC-B2 AM407397 174 19–20 21–22 17.69 4.40 5 8
IxAC-B3 AM407398 178 19–20 21–22 17.85 4.01 5 12
IxAC-B4 AM407399 175 21–22 19–20 17.88 4.14 7 7
IxAC-B5 AM407400 179 21–22 19–20, 20–21 17.66 4.15 7 11
Amino-acid sequences were deduced from the sequenced open reading frames. Indicated values were calculated from deduced amino-acid sequences using online
programs at CBS and EBI (see text). Signal peptide cleavage sites are indicated by the position of the residues between which the cleavages were predicted to occur. (a)
I. scapularis sequence [25]. (b) I. pacificus sequence [30]. (c) after removal of the predicted signal peptide at the most likely cleavage position (see text). aa, amino-acids;
MW, molecular weight; kDa, kiloDaltons; pI, isoelectric point; N-gly., number of predicted N-glycosylation sites; O-gly., number of predicted O-glycosylation sites.
doi:10.1371/journal.pone.0001400.t003..
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Figure 3. Western blot analysis of recombinant IxAC-V5His proteins from I. ricinus. Standardised amounts of recombinant IxAC-V5His proteins
from supernatants of transfected 293T cells were analysed by SDS/PAGE and detected by western blotting using an anti-V5 monoclonal antibody. A)
Parallel analysis of IxACs, B) N-deglycosylation of IxAC-B1-V5His.1, untreated, 2, incubated with PNGase (New England Biolabs).
doi:10.1371/journal.pone.0001400.g003
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from assays run in the presence of RaHBP2 or without added
protein.
Antiserum to factor B recognized purified factor B as a single
band on a non-denaturating western blot (Figure 6B). A second
band was recognized in samples from control AP assays run in the
absence of added protein or in the presence of unrelated RaHBP2.
It resolved into two distinct bands presumably corresponding to
differently charged forms of Bb [39,40]. It was absent in a sample
from AP assays run in the presence of recombinant IxACs.
We concluded that I. ricinus IxAC inhibited the formation of
C3a and cleavage of fB. Moreover, there were no detectable
differences in the degree of this inhibition between different
members of the two IxAC sub-families.
I. ricinus IxACs specifically interact with properdin
We then attempted to identify the target(s) of IxACs using ELISA
methodology. Components of C3 convertase (i.e. C3, C3b, fB, fD or
properdin) were coated on microtiter plates and incubated with
recombinant IxAC_V5His. Binding of IxACs was monitored using
an anti-V5 antibody. We first tested one member of the IxAC-A
subfamily and one from the IxAC-B subfamily. IRAC II and IxAC-
B1 purified from the baculovirus/Sf9 expression system, but not
Figure 4. Comparison of Ixodes anticomplement protein tertiary structure. Aligned IxAC amino-acid sequences from I. ricinus were submitted to
hydrophobic cluster analysis (HCA). Groups of adjacent hydrophobic residues are outlined and shaded. Proline (asterisk), glycine (open rectangle),
serine (dotted square) and threonine (open square) are highlighted. The overall distribution of hydrophobic clusters and their size, shape and
orientation are very similar.
doi:10.1371/journal.pone.0001400.g004
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unrelated protein Iris, strongly bound to properdin. They did not
bind to C3, C3b, fB or fD (Figure 7A). In addition, standardized
amounts of the seven I. ricinus IxACs but not RaHBP2 bound to
properdin in a dose-dependent manner (Figure 7B).
We also tested the binding of properdin to C3b-coated plates in
the presence of increasing amounts of IRAC II, IxAC-B1 and
control Iris. Binding was revealed by a monoclonal antibody to
properdin (Figure 7C). Increasing amounts of IRAC II, IxAC-B1
but not Iris lead to a decrease in the amount of bound properdin.
We concluded that I. ricinus IxACs specifically interacted with
properdin and prevented its binding to C3b. Again, no difference
could be discerned amongst IxACs.
IxAC proteins inhibit the formation of the C3
convertase complex by interacting with properdin
We also studied the effect of I. ricinus IxACs on the formation and
stability of the alternative pathway C3 convertase (C3bBbP). This
was reconstituted in vitro by adding purified components fB, fD and
properdin to C3b-coated plates. Bound Bb and properdin were
detected using specific antibodies. Approximately 10 times less
bound Bb was detected in the absence of properdin than in its
presence (Figure 8A). We tested the effect of one member of each
of the two IxAC subfamilies on the formation and stability of this
complex.
Figure 5. Effect of recombinant I. ricinus IxAC proteins on the alternative and classical pathways of complement activation. Assays of the
alternative (AP, solid lines) and classical (CP, dashed lines) complement activation pathway were conducted in the presence of normalized amounts of
recombinant I. ricinus IxACs produced in the supernatant of transfected 293T cells. Values for the percent inhibition of rabbit red blood cell lysis in the
presence of human serum are indicated. The values are means 6 standard deviation of triplicates. RaHBP2 was used as negative control. Black
diamond :IRAC I; black square:IRAC II; black triangle:IxAC-B1; cross:IxAC-B2; star:IxAC-B3; closed circle:IxAC-B4; Plus:IxAC-B5; open circle:RaHBP2.
doi:10.1371/journal.pone.0001400.g005
Table 4. Evidence for positive selection in I. ricinus IxAC coding sequences.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Irac I Irac II Ancestral IxAC-B1 IxAC-B2 IxAC-B3 IxAC-B4 IxAC-B5
Irac I 5.92 2.06 2.30 2.18 2.30 2.41 2.08
Irac II 0.028 1.77 2.38 2.03 2.30 2.38 2.05
Ancestral 1.000 1.000 2.82 1.92 2.54 2.46 2.07
IxAC-B1 1.000 1.000 1.000 4.13 2.63 3.39 3.28
IxAC-B2 1.000 1.000 1.000 0.223 3.63 3.28 3.17
IxAC-B3 1.000 1.000 1.000 1.000 0.435 3.25 3.57
IxAC-B4 1.000 1.000 1.000 1.000 1.000 1.000 2.51
IxAC-B5 1.000 1.000 1.000 0.491 1.000 0.441 1.000
Pairwise dN and dS values were calculated using the Nei-Gojobori method as implemented in the Mega3 package. dN/dS ratios are indicated in the upper right triangle.
Fisher’s test P values are indicated in the lower left triangle. A putative ancestral coding sequence for I. ricinus anticomplement proteins was inferred from an alignment
of the IxAC from I. ricinus coding sequences using the Ancescon package.
doi:10.1371/journal.pone.0001400.t004..
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In a first series of experiments, increasing amounts of purified
IRAC II and IxAC-B1 were added together with the individual
convertase components to C3b-coated plates. We observed a dose-
dependent decrease in the amount of bound Bb (Figure 8A) or
properdin (Figure 8B), indicating inhibition of complex formation.
At the highest protein concentrations ($200 mM), the amount of
bound Bb dropped to values observed when reconstituting the C3
convertase without properdin (Figure 8A). No such effect was
observed with the unrelated Iris protein (Figure 8).
In a second series of experiments, C3bBbP was pre-formed on
ELISA plates and then incubated with increasing amounts of
IRAC II and IxAC-B1 proteins and the unrelated control Iris
protein (Figure 8C and D). The results indicated that IxAC
proteins induced the displacement of all pre-bound factor Bb
(Figure 8C) and about 50 % of pre-bound properdin.
We also performed time-course experiments of C3 convertase
formation with (C3bBbP) or without properdin (C3bBb) in the
presence of 200 mM IRAC II, IxAC-B1 or Iris. The amount of bound
Bb was much lower in the absence of properdin than in its presence. In
this case, the presence of IxACs or Iris had no effect, indicating that the
proteins had no direct effect on the interaction between C3b and Bb.
On the contrary, the formation of C3 convertase in the presence of
properdin was strongly affected by IxACs. Values of bound Bb
dropped to values observed without properdin (Figure S2).
Overall, these results show that I. ricinus IxAC proteins inhibit the
formation of the C3 convertase complex by interacting specifically
Figure 6. Inhibition of C3a formation and factor B cleavage. Aliquots of supernatant from AP hemolysis assays conducted in the presence of
standardized amounts of IxACs from I. ricinus and unrelated control RaHBP2 were analyzed by western blotting. Panel A: Blots from gels run under
denaturing conditions were probed with monospecific anti-C3a serum. The a-chain of precursor C3 (116 kDa) and the C3a peptide (,10 kDa) are
indicated by arrows. Panel B: Blots from gels run under non-denaturing conditions were probed with a antiserum to factor B. Purified factor B was
used as a positive control.
doi:10.1371/journal.pone.0001400.g006
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with properdin. They also induce the displacement of pre-bound
properdin, and indirectly, Bb, in a dose-dependent manner.
IxAC proteins inhibit complement activation on
agarose-coated ELISA plates
We also tested the ability of IxACs to inhibit activation of the AP
on agarose-coated ELISA plates using human serum as a source of
complement factors. This experimental set-up is closer to
physiological activation of complement than protein-protein
interactions conducted on plastic surfaces. Recombinant IRAC
II and IxAC-B1 were added in the assay at various time-points
after addition of human serum (Figure 9).
The results indicated that IxAC proteins prevented C3b and
factor B deposition in agarose-coated wells when added together
with serum (not shown). They also stopped further C3 and factor B
deposition when they were added at various times (30, 45 and
60 min) after initiation of the reaction as shown by the immediate
plateauing of the curve. Nevertheless, they did not displace bound
C3 or Bb as the measured amounts of bound factors did not drop
(Figure 9). The results also showed that members of the two IxAC
subfamilies are able to inhibit the formation of C3 convertase
(Figure 9A–B and Figure 9C–D) in a similar manner. Although
they were able to stop the ongoing formation of C3 convertase
they could not undo previously formed complexes.
An additional experiment was also performed. After 60 min. of
reaction, the reaction medium was replaced with fresh buffer
containing the recombinant proteins but no human serum. A drop
in the amount of bound Bb was observed in the presence of IRAC
II or IxAC-B1 but not Iris (not shown).
These results therefore confirmed that IxAC proteins are able to
inhibit the activation of the AP on a surface by preventing
deposition of C3b and Bb.
Class specificity is observed within Vertebrates
We next tested the hypothesis that diversification of anticomple-
ment proteins helps I. ricinus counteract the complement activity of
its diverse host organisms. Freshly prepared sera from different
vertebrate species were first titrated in the AP assay in order to
define the volume causing 50% hemolysis (AH50). A wide range of
AH50 values were observed, from the equivalent of 0.25 ml per
microwell test (50 ml final volume) for Boa constrictor to 7.0 ml per
test for Balb/c mice (Table 5). Heat-inactivated samples
completely lost their hemolytic activity, confirming that this
activity was indeed due to complement (not shown).
Identical amounts of normalized IxAC proteins from I. ricinus and
control RaHBP2 were then added to the AP hemolysis assay in the
presence of AH50 volumes of serum. The 7 anticomplement
proteins reproducibly inhibited all mammalian sera in a dose-
dependent manner (Table 5 and Figure S3). In some species, such as
humans (Figure 3) or B. Taurus and M. musculus (Figure S3) the dose-
response curves were similar for the seven IxACs from I. ricinus. In
other mammals such as, C. familiaris, O. aries, S. domesticus and C.
elaphus (Figure S3) lower doses of the proteins had different
efficiencies. They all reached similar plateau values at higher doses
of protein, though. We also observed that most species were not
equally sensitive to IxAC inhibition of the AP. Thus hemolysis of
rabbit red blood cells by mouse serum was inhibited by not more
than ,30% whereas the hemolytic activity of human serum was
inhibited at ,85 %. Intermediate plateau values were observed for
the other species tested (Figure S3). On the contrary, IxACs from I.
ricinus did not affect most bird and squamate reptile sera, with the
exception of IRAC II and IxAC-B4, which inhibited AP activity of
one bird (Phasianus colchicus) and one snake (Elaph guttata), respectively.
Figure 7. ELISA analysis of the binding of IxAC proteins to
immobilized C3 convertase components. Panel A: Binding of IxACs
to AP components. Purified recombinant IRAC II, IxAC-B1 or unrelated
protein Iris were added to microtiter wells previously coated with
purified factors C3, C3b, fB, fD or properdin (P). Bound proteins were
detected with an anti-V5 monoclonal antibody using an ELISA format.
Light dotted histogram: IRAC II; dark dotted histogram: IxAC-B1; black
histogram: Iris. Panel B: Increasing amounts of normalized supernatant
from transfected culture 293T cells were added to immobilized
properdin. Bound IxACs were detected with an anti-V5 antibody. Black
diamond: Iris; black square: IRAC I; black triangle: IRAC II; cross: IxAC-B1;
star: IxAC-B2; closed circle: IxAC-B3; plus: IxAC-B4; minus : IxAC-B5. Panel
C. Competition between properdin and IxACs for C3b binding. Purified
properdin and increasing amounts of IRAC II, IxAC-B1 or unrelated
control IRIS were added simultaneously to C3b-precoated microtiter
wells. Bound properdin was detected with an anti-properdin monoclo-
nal antibody. Black diamond: IRAC II; black square: IxAC-B1; black
triangle: Iris.
doi:10.1371/journal.pone.0001400.g007
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To summarize, all 7 IxAC from I. ricinus inhibited the AP in all
mammal species tested. Inhibition of the AP in only one bird by
only IRAC II and only one squamate species by only IxAC-B4 was
also observed.
Expression patterns of individual I. ricinus IxACs
Primer pairs designed to specifically detect each IxAC messenger
(Table S3) were used to analyse their pattern of expression by RT/
PCR in individual ticks, at various stages of their life cycle and
during the bloodmeal.
We first investigated IxAC expression during the life cycle. All 7
IxAC sequences were detected in polyA+ RNA from the original
pool of 70 salivary glands from adult females. No PCR product was
observed from poly A+ RNA that had not undergone reverse
transcription, indicating that we did not amplify fragments of
genomic DNA (Figure 10a). Younger stages of the life cycle (larvae
and nymphs) expressed IRAC I, IxAC-B1, B3 and B5 (Figure 10b).
We also investigated whether they expressed additional anticomple-
ment proteins not found in adults by searching for the full coding
sequences in 10 pooled nymph and 10 pooled larvae cDNA in high-
fidelity conditions using primer pairs designed from the 59 and 39
ends of IxAC-A or IxAC-B coding sequences (Table 1). Primers
amplified the expected ,600 bp products which were then inserted
into pCRII and sequenced. Only IRAC I was retrieved from
nymphs (7 independent clones), and IxAC-B1 and IxAC-B5 from
larvae (2 and 1 clones respectively). The ‘‘nymphal’’ or ‘‘larvae’’
nucleotide sequences were 100% identical to ‘‘adult’’ ones.
We then investigated the expression of the IxAC repertoire
during the bloodmeal. Messengers for IRAC I, IRAC II, IxAC-B1,
IxAC-B3 and IxAC-B5 were detected in unfed females and the
complete repertoire was detected in salivary glands from females
on day 3 of the bloodmeal and on day 5 (Figure 10b).
When analysing the pattern of IxAC expression in 10 individual
adult females we found that no single specimen expressed the
whole range of anticomplement IxAC proteins. Each individual
tick expressed one (1 tick), two (6 ticks) or three proteins (3 ticks).
IxAC-B1 was expressed in 8/10 ticks tested, followed by IxAC-B3
and B4 (3/10), then IRAC I, IRAC II, IxAC-B2 and B5 (2/10).
Four individual ticks expressed members of both IxAC-A and
IxAC-B and 6 individual ticks expressed only members of IxAC-B.
None expressed solely members of IxAC-A.
Taken together, the results indicated that IxAC are expressed in
all ticks tested, throughout the bloodmeal and at all the development
stages examined. There was no evidence for stage-specific variants
although some members of the family may be induced or up
regulated during the first days of the bloodmeal and in the adult.
Individual females expressed individual members of the family and
no individual tick expressed the complete series of I. ricinus IxACs.
Figure 8. Effect of IxAC proteins on the formation and stability of C3 convertase. Panel A and B: The effect of IxAC proteins on the formation of C3
convertase was evaluated by incubating simultaneously purified factors B, D and properdin with increasing amounts of IRAC II or IxAC-B1 on C3b-
coated wells. Panel C and D: The effect of IxAC proteins on the stability of C3 convertase was assessed by incubating preformed C3 convertase (fB, fD
and properdin pre-incubated for 1 hour) on C3b-coated plates with increasing amounts of recombinant IxACs. Bound factor B or properdin was
detected with an anti-factor B antibody (A–C) or anti-properdin antibody (B–D), respectively. Recombinant IRIS was used as negative control. Black
diamond: IRAC II; black square: IxAC-B1; black triangle: IRIS.
doi:10.1371/journal.pone.0001400.g008
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Figure 9. Effect of IxAC proteins on the deposition of C3b and factor B on agarose-coated plates. Loading human serum on agarose-coated
microplate wells activates the alternative complement pathway. Purified recombinant IRAC II (A–B) or IxAC-B1 (C–D) were added after 30, 45 or
60 minutes. The reactions were stopped at various times. C3b and factor B deposition was detected using anti-C3 antibody (A–C) or anti-factor B
antibody (B–D), respectively. Black diamond: no added protein; black square: 30 min.; black triangle: 45 min.; cross: 60 min.
doi:10.1371/journal.pone.0001400.g009
Table 5. Host specificity of anticomplement activity by recombinant IxACs from I. ricinus.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Serum source AH50 Irac I Irac II IxAC-B1 IxAC-B2 IxAC-B3 IxAC-B4 IxAC-B5 RaHBP2
1. Homo sapiens (4) 2.4 + + + + + + + 2
2. Canis familiaris (3) 1.7 + + + + + + + 2
3. Ovis aries (5) 2.3 + + + + + + + 2
4. Sus domesticus (2) 4.5 + + + + + + + 2
5. Bos Taurus (3) 1.7 + + + + + + + 2
6. Cervus elaphus (3) 0.8 + + + + + + + 2
7. Mus musculus (10) 7.0 + + + + + + + 2
8. Phasianus cochicus (5) 1.3 2 + 2 2 2 2 2 2
9. Gallus gallus (4) 2.2 2 2 2 2 2 2 2 2
10. Meleagris gallopavo (1) 1.6 2 2 2 2 2 2 2 2
11. Columba liva (5) 1.0 2 2 2 2 2 2 2 2
12. Tropidurus torquatus (2) 1.50 2 2 2 2 2 2 2 2
13. Boa constrictor (1) 0.30 2 2 2 2 2 2 2 2
14. Elaph guttata (3) 0.20 2 2 2 2 2 + 2 2
We assessed the ability of individual recombinant IxACs proteins to inhibit the alternative pathway (AP) of complement in sera from various vertebrate species as
indicated. AP activation was assessed by hemolysis of added rabbit erythrocytes. (+) and (2) indicate the existence or absence of a dose-response relationship between
added recombinant proteins and percent inhibition of hemolysis. AH50 value, serum amount (ml) that causes 50 % hemolysis of rabbit erythrocytes in 50 ml of the AP
assay. Host N-u 1–7: mammals; 8–11: birds; 12–14: Squamates. Values between brackets indicates the nu individuals from which the serum pools were constituted.
doi:10.1371/journal.pone.0001400.t005..
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Antigenic diversification in the IxAC family in I.
ricinus
A monospecific mouse antiserum to IxAC-B1 was produced in
mice by DNA immunization followed by a booster with purified
recombinant IxAC-B1. It was used to perform western blot
analysis of standardized amounts of IRAC I to IxAC-B5 (see
Figure 3a) in parallel with the anti-V5 commercial antibody. As
shown in Figure 11A, mouse anti-IxAC-B1 serum only recognized
IxAC-B1 and none of the other IxACs from I. ricinus. This shows
that epitopes recognized on IxAC-B1 in this assay were not present
on any other member of the family.
The neutralizing potential of these antibodies was also assessed.
Standardized amounts of 7 recombinant IxACs from I. ricinus were
pre-incubated with heat-inactivated anti-IxAC-B1 serum before
assessing their ability to interfere with complement activity.
Neutralization of AP inhibition activity as indicated by recovery
of RBC lysis was observed only against IxAC-B1 (Figure 11B).
Seroneutralization of AP inhibition by IxAC-B1 was not observed
with pre-immune sera or with antisera directed to the unrelated
protein Iris (not shown).
These data show that an antiserum raised against one member
of the IxAC family is able to recognize and functionally inhibit this
member alone and no other member of the family. It suggests that
immunodominant epitopes of a member of the family are not
shared by other members.
DISCUSSION
The interaction between hard ticks and their hosts is a good
example of an ongoing ‘‘arms race’’ between a parasite and its
host. As the tick feeds on its vertebrate host for periods of several
days it must counteract all the host’s defense mechanisms
including hemostasis, inflammation and the immune response.
This is accomplished by injecting batteries of active proteins in the
saliva. Most are coded by multigene families only a few of which
have been fully characterized. In this work we have attempted to
provide an exhaustive analysis of one such family, the family of
salivary inhibitors of the alternative complement pathway in Ixodes
ricinus. Our analysis includes: i) a complete or nearly complete
inventory of members of the family, ii) a detailed study of its action
mechanism: these proteins bind to properdin, a positive activator
of complement, thereby preventing early rejection of the tick by
the innate response, and iii) investigation of the possible selective
pressure causing diversification: sequence diversification comes
with antigenic diversity and helps circumvent the host’s adaptive
immune response.
A large family of complement inhibitors in the hard
tick I. ricinus
We describe five new anticomplement sequences (AM407396 to
AM 407400) from the hard tick Ixodes ricinus. These share less than
Figure 10. Expression patterns of individual IxACs. PolyA+ RNA was extracted from various I. ricinus material as indicated and reverse transcribed.
The resulting cDNAs were submitted to PCR analysis using pairs of primers specific for the indicated IxACs. Non- reverse transcribed polyA+ RNA from
the pool was included as negative control (Ctrl). PCR products were run on 1.2 % agarose gels. M, DNA size markers. B1 to B5, IxAC-B1 to IxAC-B5.
Sizes in bp are indicated. Panel A: Analysis of salivary glands of a tick population (70 specimens, pool) and from individual female ticks at day 5 of the
bloodmeal (A to J). Panel B: Analysis of pooled salivary glands of tick female populations at day 0 (25 specimens), day 3 (25 specimens) and day 5 (70
specimens) of the bloodmeal as well as from pooled gorged nymphs (25 specimens) and larvae (25 specimens).
doi:10.1371/journal.pone.0001400.g010
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40 % amino-acid identity with previously described ISAC of I.
scapularis [25] and with IRAC I and IRAC II from I. ricinus [31].
The new sequences clustered in a distinct group of anticomple-
ment sequences as indicated by phylogenetic analysis (Figure 1).
We also proposed the acronym ‘‘IxAC’’ for Ixodes Anti-
Complement to the larger family of Ixodes anticomplement
proteins related to prototypical ISAC.
Our analysis provides a reasonably exhaustive and accurate
inventory for the tick population under study. This is supported by
several lines of evidence: i) 12 RT/PCR inventories performed
independently on two different cDNA using 6 different primers
pairs consistently yielded the same set of sequences; ii) Sequences
identical to previously described IRAC I and IRAC II were
recovered; iii) IxAC-B1 and IxAC-B2 were first discovered by
serendipidity and then repeatedly found again by RT/PCR
analysis of salivary gland cDNA. The existence of additional
variants (either alleles or paralogs) in the larger I. ricinus species
may be investigated on specimens captured in the field or on
specimens from other laboratory colonies.
We also noticed consistent differences in the frequency of the 7
I. ricinus IxACs in RT/PCR inventories (Table S1). This may be
due to the differential expression of IxAC genes in individual ticks
(Figure 10). Alternatively, different steady-state levels of messen-
gers may also be responsible.
The following arguments are consistent with the theory that the
7 I. ricinus IxAC genes are paralogs rather than alleles: i) The 7 I.
ricinus IxAC proteins are not very closely related (65% amino-acid
identity at most), ii) They could not be grouped together into a
single phylogenetic cluster, iii) They were cloned from a restricted
tick population, iv) Some individual female ticks expressed up to 3
IxACs simultaneously, indicating the existence of at least two loci.
Daix et al. [31] developed specific monoclonal antibodies that
can differentiate IRAC I and IRAC II by immunofluorescence
analysis on dissected salivary glands. They observed co-expression
of the two proteins in the salivary glands of 12 adult specimens
collected in various woodland locations throughout Belgium. The
authors concluded that IRAC I and IRAC II are not alleles but
rather co-expressed members of a multigene family. However, in
Figure 11. Antigenic specificity of recombinant IxACs from I. ricinus. Standardised amounts of the seven I. ricinus recombinant IxACs were analysed
for antigenic specificity. Panel A. Western blot analysis. The serum from a mouse immunized against IxAC-B1 by genetic immunization followed by a
protein boost recognised solely recombinant IxAC B1. M, molecular weight markers (Mark12, Invitrogen). Panel B. Seroneutralization experiments. AP
hemolysis assays were conducted with and without the seven recombinant IxACs. 100% hemolysis was obtained in the absence of anticomplement
protein (light dotted histogram). Recombinant IxACs alone (dark dotted histogram) or recombinant IxACs plus heat-inactivated sera from mice
immunized against IxAC-B1 (anti IxAC-B1, black histogram) or mock immunized mice (anti-PBS, white histogram) were added as indicated.
Neutralization of activity as indicated by a recovery of hemolysis, was observed only on IxAC-B1. Upper panels: seroneutralization of IxAC-A subfamily.
Lower panel: seroneutralization of IxAC-B subfamily. Error bars represent standard deviations.
doi:10.1371/journal.pone.0001400.g011
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our RT/PCR analysis, IRAC I and IRAC II mRNA were
detected together only twice in 10 individual specimens from the
Neuchaˆtel breeding colony. This discrepancy may be due to cross
detection of other members of the IxAC families by monoclonal
antibodies directed against IRAC I and IRAC II.
Phylogenetic analysis
Phylogenetic analysis of the nucleotide and amino-acid sequences
by distance and maximum likelihood methods (Figure 1) indicated
that all known Ixodes anticomplement proteins (IxACs) could
robustly be grouped into two large groups or subfamilies: IxAC-A
and IxAC-B. IxAC-B only contains our five new sequences from I.
ricinus whereas IxAC-A contains all the other sequences. IxAC-A
can be further subdivided into ‘‘ISAC-like’’ and ‘‘Salp9-like’’
clusters after the name of the founder sequences. Regardless of the
method used, placement of IRAC I within the ISAC-like or Salp9-
like cluster was not supported by bootstrap analysis. It therefore
probably represents a third cluster within the IxAC-A family.
The presence of IxAC sequences in I. ricinus, I. scapularis and I.
pacificus indicated that their last common ancestor and possibly the
ancestral Ixodes tick possessed an IxAC-like sequence. The lack of I.
scapularis and I. pacificus representatives in IxAC-B is best explained
by methodological differences when looking for IxAC sequences in
these two species. Indeed, we performed a dedicated family-
specific inventory in I. ricinus whereas the I. scapularis and one I.
pacificus entries are the result of large-scale untargeted sequencing
of large numbers of clones taken at random or PCR screening
using unique primers designed from ISAC and Salp20. Dedicated
RT/PCR inventories of IxAC sequences in I. scapularis and/or I.
pacificus would help resolve this question by showing whether or
not the two species express members of IxAC-B.
IxAC homologs were not detected by RT/PCR analysis of R.
appendiculatus salivary gland cDNA or by in silico interrogations of
collections of available non-Ixodes (Metastriata) sequences. IxAC
homologs, if any, in R. appendiculatus might be too divergent to be
amplified by our PCR primers. Besides, the present coverage of
Metastriata genomes in public databases may be very limited. On
the other hand, our finding is consistent with the absence of reported
inhibition of the alternative complement pathway by Metastriata.
Positive (diversifying) selection of coding sequences
Since Ohno [41], gene duplication has been considered to be an
important factor in evolution as it leads to the evolution of new gene
functions. In higher organisms most genes belong to families of
related genes formed by repeated gene duplication events during
evolution [42].Considerable research is currently being carried out
in order to understand the forces leading to and shaping multigene
families in living organisms [43].Ticks are particularly suited for this
analysis as their salivary proteins are coded by multigene families, a
feature probably related to their bloodfeeding lifestyle.
As far as salivary proteins in general are concerned, the process of
gene duplication accompanied by positive selection leading to the
acquisition of novel protein functions is documented in snake venom
proteins [44,45] and in soft tick salivary proteins [46]. In the
bloodfeeding diptera Lutzomyia longipalpis, variants of the maxadilan
protein retain the same function and biochemical properties [47] but
have undergone diversifying selection (Lanzaro, personal commu-
nication). This is associated with antigenic diversity leading to escape
from the host’s antibody response [48,49].
We compared the coding sequences of the seven I. ricinus
anticomplement sequences with one another as well as with a
putative reconstructed ancestral sequence. We observed that
percent identities between IxAC amino-acid sequences were
consistently lower than percent identity at the nucleotide level.
In addition, dN/dS ratios were consistently higher than 1. We
concluded that IxAC coding sequences had been subjected to
strong positive selection within the I. ricinus species. In other words,
diversification of the IxAC amino-acid sequences was strongly
selected for and this was not associated with speciation. This
confirms the conclusion of a restricted analysis conducted on only
two members of the family: Daix et al. [31] observed an excess of
non-synonymous changes when they compared IRAC I, IRAC II
and anticomplement sequences from I. scapularis and I. pacificus (i.e.
members of the IxAC-A subfamily).
We examined the type of the selection pressure operating on the
IxAC family in I. ricinus by specifically investigating the following
possibilities i) structural and biochemical diversity, ii) mechanism
and functional diversity, iii) adaptation to host species, iv) stage
specificity, v) antigenic diversity.
Structural and biochemical diversity
We first assessed the differences in the biochemical properties of
the members of the IxAC family. Predicted and experimental
biochemical properties of the seven proteins were analysed and
compared to those of ISAC from I. scapularis and ISAC-I from I.
pacificus. We observed very similar values for calculated pI and
observed and calculated molecular weights. All recombinant
proteins were exported in the supernatant as predicted by
specialized algorithms. They were highly glycosylated and
disulphide bonds were predicted in all of them (this article and
ref. [25,29]). Finally, comparison of the distribution of hydropho-
bic clusters in the amino-acid sequences predicted identical or very
similar folds or tertiary structure in all IxACs.
Mechanism and function diversity
The kinetics of inhibition of the alternative complement pathway
in human serum were similar for all 7 recombinant IxACs from I.
ricinus. The classical pathway was not affected. This is also a
feature of the I. scapularis anti-complement proteins ISAC [25] and
Salp20 [29] and it has been reported recently for I. ricinus IRAC I
and IRAC II by Daix et al. [31]. We then investigated the action
mechanism of the 7 I. ricinus IxACs. Protein binding and
competition experiments suggested that all 7 proteins had the
same action mechanism. This is consistent with the similar
properties of members of the family and also with the identical or
very similar predicted folds or tertiary structures. We conclude that
IxAC sequence diversification is not primarily driven by selection
for different biochemical properties and tertiary structure, or a
change in the roles of the proteins. Minute differences are possible
but they remain to be investigated.
Our study of this action mechanism showed that IxAC
molecules bind specifically to properdin, preventing its association
with C3 and thereby reducing formation of C3 convertase
complex to levels observed in the absence of properdin. They
also induce destabilization of pre-formed C3bBbP convertase.
They consequently inhibit the activation of complement via the
alternative pathway. Properdin (factor P) is known to increase ten
times the half-life of C3bBb convertase although functional
convertase activity may be obtained in its absence [12,50,51].
The effect of IxAC proteins may therefore be explained by a
decreased stability of C3 convertase due to blocking of properdin.
This is reminiscent of the effect of monoclonal antibodies that bind
to properdin and knock out of the properdin gene in mice, and
both lead to inhibition of the AP [19].To our knowledge this is the
first time that direct interaction with properdin is described as a
mechanism of complement regulation.
15
Two recent reports further emphasize the importance of
properdin in the AP: Spitzer et al. [52] and Kimura et al. [53]
showed that properdin can also bind directly to microbes, initiating
assembly of C3BbP convertase and complement activation. Whether
properdin is a positive regulator or an initiator of the AP, it is a
central element and a critical molecular target for inhibitors.
Nevertheless, it remains to be seen whether IxACs can also interfere
with the binding of properdin to the target surface.
Ixodid ticks are pool feeders, they dilacerate small blood vessels
at the bite site, generating a small haemorrhage or pool of blood in
which saliva is injected and from which they pump blood [3].
Local inhibition of complement activation in the pool of blood is
therefore beneficial for at least two reasons. Firstly, inhibition of
the production of pro-inflammatory peptides will help prevent the
inflammation response at the bite site; secondly, inhibition of
MAC insertion on the mouthparts and midgut epithelium will
prevent the destruction of tick tissue by complement factors
present in the blood meal.
In order to obtain that effect, ticks must secrete sufficient
amounts of the inhibitor. A very rough calculation of the amount
required can be made. This must take into account properdin
concentration (,5 mg/ml in normal human plasma) [54,12], the
amount of ingested blood (little information is available about this
volume which is probably several hundred microliters [3]), the
amount of secreted saliva (unknown but limited by the amount of
ingested blood as blood water is recycled into saliva) and the
concentration of IxAC in the saliva. If there is complete recycling
of blood water into saliva and an equimolar properdin-IxAC
interaction, the IxAC concentration required may be estimated to
be approximatively 1 ng/ml. However, the anti-complement effect
needs only be local (i.e. in the immediate proximity of the mouth
parts and midgut epithelium), and this drastically reduces the
amount of complement to be neutralized. Moreover, the IxAC
might not mediate the only anti-complement mechanism in Ixodes
saliva. Inhibition of the IxAC expression in ticks by RNAi may
help reveal additional anticomplement molecules.
Finally our results suggest that one molecule of IxAC may
interact with several molecules of properdin. Thus, in the
experiment shown in figure 7c, complete inhibition of binding of
200 ng of properdin to C3b was observed with around 25 nm
inhibitor, corresponding to an IxAC/properdin molecular ratio of
1/3 to J. This is consistent with the finding that properdin is
present in the serum as dimer, trimer and tetramer [55] forms.
One IxAC molecule may therefore interact with one properdin
polymer. This hypothesis is open to experimentation and is
currently being tested in our laboratory.
The mechanism by which salivary gland extract (SGE) from I.
ricinus inhibits the AP has been explored by Lawrie et al. [39].
They observed inhibition of the cleavage of fB to Bb and C3a
production when rabbit erythrocytes were used as activators and
complete human serum as a source of complement. Little or no
C3b was observed on erythrocytes in the presence of SGE.
Reconstitution of the alternative C3 convertase (C3bBb) in vitro
from purified C3b, fB and fD (but not properdin) was not affected
by SGE. Moreover, SGE had no effect on the cleavage of 125I-C3
into 125I-C3b by preformed C3bBb or when it was added
simultaneously with C3b, factor B and factor D. These findings are
similar to our results and may therefore be fully explained by the
action of IxAC proteins in the saliva.
Lawrie et al. [39] also noticed that SGE provoked the cleavage
of a ,5 kDa peptide at the C-terminal end of purified C3 a
chains. The product can apparently still be cleaved by preformed
convertase to yield C3a. The authors also suggested that the larger
fragment may not be able to participate in convertase formation.
However, we were unable to reproduce this finding (data not
shown). As saliva is a complex mixture of proteins, proteolytic
cleavage of C3, as well as other possible additional mechanisms,
may also be involved in inhibition of the AP.
Saliva, recombinant ISAC [25] and Salp20 [29] from I.
scapularis as well as IRAC I and IRAC II from I. ricinus [31],
have been previously tested for their ability to inhibit AP activation
in experiments using human serum as source of complement and
agarose as activating surface. The authors observed inhibition of
the deposition of both C3b and Bb and release of pre-bound Bb
but not pre-bound C3b from the plates. Release of C3b is not
observed because this protein is covalently linked to agarose.
Finally, recombinant Salp20 also inhibits the production of C3a
and deposition of C3b on the surface of red blood cells in the AP
hemolytic assay [29]. We conclude that the novel inhibition
mechanism described here is consistent with published data
concerning Ixodes tick saliva, salivary gland extracts, or recombi-
nant anticomplement proteins.
Comparison of IxACs with other anti-complement
inhibitors
Complement is a critical component of innate and adaptive
immunity mainly acting through specific cell lysis, the release of
potent pro-inflammatory peptides and opsonization of target cells.
To prevent tissue damage by over-activation, complement activation
is subject to tight regulation by many physiological negative
regulators. These include surface and soluble proteins such as
Decay-Accelerating Factor (DAF/CD55), Complement Receptor-1
(CR1/CD35), and factor H. They compete with factor B for binding
to C3b and facilitate dissociation of the C3bBb complex. Together
with the membrane protein MCP/CD46, they also act as cofactors
for factor I (fI), a serine protease leading to C3b inactivation by
proteolysis. Finally, other membrane proteins such as CR2/CD21,
protectin or CD59 protect the host cell membrane from inappro-
priate complement activation and cell destruction [9].
Many pathogens also target components of the complement
system, sometimes taking advantage of existing physiological
regulation mechanisms. Some pathogenic bacteria such as Borrelia,
Neisseria, Streptococcus and Yersinia express receptors that bind host-
derived soluble complement regulatory proteins, in particular
factor H, FHL-1, and C4b binding protein [56]. Certain
pathogenic viruses express proteins homologous to vertebrate
complement regulators such as vaccinia complement control
protein or apparently unrelated functional analogs [57]. Protein
NS1 of West Nile Virus recruits soluble fH [58]. Surface protein
gC of Herpes Simplex Virus binds to C3b and inhibits its
association with C5 and properdin [59].
Parasitic protozoa such as Leishmania spp. and Trypanosoma cruzi
are also able to counteract complement activation. In the former,
the major surface protein GP63 is a protease that can cleave C3b
to inactive iC3b. The latter expresses a 160 kDa homolog of DAF
which binds to C3b and C4b and prevents formation of the
convertase [60].
In the soft tick Ornithodoros moubata, lipocalin OmCI binds to
component C5 and prevents interaction with C5 convertase or
blocks the C5a cleavage site. It prevents generation of C5a and
MAC and thus suppresses complement hemolytic activity while
preserving the immune clearance and opsonization functions [33].
Cobra venom factor (CVF) is a homolog of cobra C3. It is a
functional analog of C3b as it binds to factor B which is cleaved by
factor D to form the CVF:Bb complex. This is a stable convertase
that continuously cleaves component C3 and C5, leading to
depletion of serum complement components [61].
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Finally, complement is also considered as a privileged target for
new therapeutic agents. They comprise serine protease inhibitors
(as many components of the complement cascade are serine
proteases), soluble versions of physiological complement regula-
tors, chemical complement inhibitors, complement receptor
antagonists and therapeutic antibodies [62]. For instance, the
anti-C5 humanized antibody or eculizumab which inhibits the
generation of both C5b and anaphylatoxin C5a is currently tested
in clinical studies against autoimmune inflammatory diseases such
as rheumatoid arthritis, glomerulonephritis and lupus erythema-
tosus and has recently been shown to be effective against nocturnal
paroxysmal hemoglobinuria [63].
As compared to these inhibitors, IxACs have a completely new
action mechanism as they bind and prevent the action of
properdin, a factor that has not yet been found to be negatively
regulated. The only noticeable structural feature of IxAC proteins
is the presence of 4 conserved cysteine residues predicted to make
two disulphide bridges. These are also found in repeated,
conserved motifs of ,60 residues known as short consensus
repeats (SCR’s) characteristic of regulators such as fH [64].
Otherwise, there was no sequence homology or structural
resemblance as indicated by the HCA method (data not shown).
Moreover, no experimental determination of the 3D structure has
yet been published and database interrogations yielded no hits
with known 3 D structures (data not shown). Therefore, IxAC-
mediated inhibition of the AP appears to be a novel mechanism
both in terms of the molecular interactions involved and the
structure of the inhibitor.
What would be the advantages of such a mechanism if IxACs
are considered to be putative drugs? First, IxACs target the only
physiological positive regulator of complement activation. Sec-
ondly, it acts very early in the AP cascade and in any case
upstream of most known inhibitors. In addition, as properdin has
recently been described to also be an initiator of AP [52,53],
IxACs may have a double action on AP, both on initiation and
stabilization. Furthermore, properdin strictly acts at membrane
level, mostly by stabilizing preformed C3 convertases complexes.
Therefore IxAC inhibitors have a localized, highly targeted action,
unlike many putative anticomplement drugs which have a systemic
action [65]. Finally, it acts specifically on the AP, while many
drugs on trial target either the classical pathway or, like C3
inhibitors, both the classical and alternative pathways. Even anti-
properdin antibodies also have a significant inhibitory action on
the classical pathway of complement activation [19]. The
specificity of IxACs for the AP has two major consequences.
Insofar as clinical treatment is considered, a major concern for
anticomplement drugs is that by inducing a complete blockade of
the complement system, they increase susceptibility to infections
and/or trigger autoimmune-like symptoms [66]. The detrimental
effects of complement inhibition would be significantly lowered by
specific inhibition of the sole AP, with no action on most of the CP
effects. This application is theoretically feasible as the only critical
adverse effect of AP inhibition is an increased susceptibility to
neisserial meningitis [62].
One limitation we foresee is the case of diseases in which the
respective involvement of AP and CP are unknown or intricate.
The therapeutical benefits of AP inhibition will then be difficult to
evaluate.
Absence of stage specificity
We also investigated the developmental and bloodmeal stage
specificity of expression. In databases, I. scapularis IxAC entries are
reported from adults and nymphs but no robust ‘‘adult-only’’ or
‘‘nymphal-only’’ cluster appeared in our phylogenetic analysis.
Moreover, we found one instance where the same nucleotide
sequence was reported in both stages. In I. ricinus, we detected
IxAC messengers from both IxAC-A and IxAC-B by RT/PCR in
all stages of the life cycle and there was no evidence for stage-
specific sequences. However, not all seven IxACs were detected in
larvae and nymphs, as we observed expression of only IRAC I,
IxAC-B1, B3 and B5 in fed larvae and fed nymphs.
We also investigated the expression of the IxAC repertoire
during the bloodmeal. IRAC I, IRAC II, IxAC-B1, B3 and B5
messengers were detected in unfed females and the complete
repertoire was detected in salivary glands from pooled females at
days 3 and 5 of the bloodmeal.
These results suggest that variability in the IxAC family is not
due to the development of proteins specific for a development
stage or a phase of the bloodmeal. It is still possible, however, that
some members are induced or upregulated in the first days of the
bloodmeal or in the adult. Alternatively, the apparent absence of
certain messengers in unfed adults and in younger stages may be
due to the fact that individual ticks expressed only one or a few
IxAC. This may be answered by analyzing larger pools of larvae,
nymphs and unfed adult salivary glands.
Finally, variability in IxAC expression by individual adult
females was observed: individual adult females each expressed
different individual or series (up to three) of IxACs although some
variants such IxAC-B1 were expressed more often than others.
Adaptation to host species
A rationale for IxAC variability may be the necessity for the tick to
be able to inhibit AP activity from a wide range of hosts. Indeed, I.
ricinus is known to infest a very large range of mammals, birds and
some reptiles [3,67] and it is possible that I. ricinus can infest any
terrestrial vertebrate it encounters [68,69].
Lawrie et al [24] compared the anticomplement activity of adult
salivary gland extract (SGE) from several Ixodes species against a
series of birds and mammals. The authors attributed the observed
differences in anti-complement activity to host specificity of
different tick species.
Recently, Schroeder et al. [70] compared the anticomplement
activity properties of recombinant IRAC I and IRAC II on fresh
serum from human, dog, horse, sheep, rat, pheasant and pigeon.
They observed inhibition of human, canine, sheep, horse, pig and
pheasant serum by both IRAC I and IRAC II. Neither inhibited
pigeon or rat serum.
We extended this analysis to the seven IxACs in I. ricinus and a
larger and more diverse panel of host species. Dose-dependent
inhibition of the AP by all recombinant IxACs was observed in
sera from all mammals tested. For birds, only pheasant serum was
inhibited, by IRAC II alone. In addition, AP activity in the serum
of the snake Elaph guttata was inhibited by IxAC-B4. Our results
with IRAC I and IRAC II were identical to those of Schroeder
except for pheasant serum where we noted no inhibition with
IRAC I. However, the inhibition was very low in their study [70].
Small experimental differences may explain the different conclu-
sion, i.e. ‘‘low level’’ rather than ‘‘absence’’ of inhibition.
As every IxAC can inhibit the AP in all mammals tested, we
conclude that diversification is not due to host specificity within the
Mammalia class. Rather, it appears that IxAC evolved as a
mammal-specific pathway for AP inhibition. The fact that
inhibition of AP activity is only induced by some IxACs in only
one bird and one reptile might seem surprising given the very wide
specificity of I. ricinus. This is fully explained, though, by the
absence of properdin in Birds and Squamates as reported by
Nonaka & Kimura [71]. IRAC II and IxAC-B4 might accidentally
bind to other components of the complement system such as C6,
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C7, C8 and C9 of the MAC, as they also possess repeats of the
TSR (TSP1) motif characteristic of Properdin [14]. Therefore,
Ixodes ticks might rely on other mechanisms to inhibit the AP or
complement effector mechanisms when feeding on most birds and
reptiles (e.g. proteolysis of the C-terminus of the C3 a chain
described by Lawrie et al. [39]).
Alternatively, as birds and reptiles have not been studied as
exhaustively as mammals, it cannot be ruled out that properdin is
present in some species or lineages but not in others. Besides, bird-
specific and/or lizard-specific IxAC variants may not yet have
been found. All the ticks used in this study have been bred on mice
and rabbits in the laboratory for over 20 years from founder
specimens initially captured in the surroundings of Neuchaˆtel in
Switzerland. Therefore, they probably have a reduced genetic
diversity and have been selected for efficient blood feeding on
mammals. Tick specimens collected on infested birds and lizards
will help resolve these questions.
Although all recombinant IxACs inhibited the AP in all
mammals tested, quantitative differences appeared in the ability
of various IxACs to inhibit the AP in a given host and in the ability
of a given IxAC to inhibit the AP in different hosts. Sequence
differences between the IxACs might result in species specificity.
Indeed although the general 3D structure of IxACs appears to
have been conserved, small changes might modulate their
interaction with properdin. Preliminary analysis of properdin
amino-acid sequences from different eutherian mammals (H.
sapiens, M. musculus, C. familiaris, E. caballus) indicated a 75 to 79%
identity between the mature proteins (B. Couvreur, unpublished).
Although properdin is a very highly conserved protein in
eutherians, it is conceivable that small differences in amino acid
sequences may lead to changes in affinity for the inhibitors.
Furthermore, sequence comparison between individual thrombos-
pondin domains suggested that TSR5 is more variable than the
other TSR domains (B. Couvreur, unpublished). Because TSR5 is
involved in the interaction of properdin with C3b [55] and as
IxAC displaces this interaction, it is tempting to speculate that
TSR5 variability could lead to different affinities for IxAC
inhibitors, different degrees of inhibition of C3b binding and
differences in the level of inhibition of the AP hemolysis assay.
Alternatively, several other factors might also explain the observed
differences between mammalian sera. These include i) different
properdin concentrations in the plasma from different species, ii)
different concentrations of C3 and other complement components,
iii) different relative roles of properdin (stabilizer of C3 convertase
versus activator of the AP) in the various species tested.
Whatever the explanation, these differences were not further
investigated as they have no impact on the general conclusion of
this study.
Antigenic diversification
One of the most frequent countermeasures adopted by parasites
against the host’s immune system is antigenic variation. It allows
the parasite to escape the adaptive response but also to prevent
immediate rejection in a new host by an immune memory reaction
following a previous contact.
Tick anticomplement proteins are immunogenic to mammals
and antibodies are present in the serum of repeatedly infested
rabbits and guinea pigs [28]. Furthermore, we showed here that
mice antibodies can neutralize anticomplement activity. siRNA
experiments on nymphs have shown that silencing ISAC -like
molecules in I. scapularis leads to a dramatic reduction in
bloodmeal survival of feeding nymphs [27] indicating the
importance of anticomplement proteins for the parasite. An
immune response to anticomplement proteins may therefore be a
major threat to completion of the bloodmeal or even tick survival.
Our finding that members of the IxAC family of proteins in I.
ricinus do not share immunodominant epitopes and that individual
ticks express different IxAC variants indicate that part of a tick
population are probably able to escape an anti-IxAC immune
response. Antigenic variability may therefore be considered to be a
selective advantage at population level. This is a likely explanation of
why IxAC evolved in a multigene family undergoing diversification.
Possible clinical roles of IxACs
Many diseases are caused either by an insufficiency or over-
functioning of complement. The former mostly leads to increased
susceptibility to infectious agents [62]. The latter is associated with
a large number of diseases including inflammatory disorders (e.g.
asthma, sepsis); disorders related to severe tissue injuries (e.g. burn
injury, myocardial infarction, ischemia/reperfusion), auto-im-
mune diseases (e.g. lupus erythematosus,glomerulonephritis,
rheumatoid arthritis, psoriasis, multiple sclerosis) and degenerative
diseases (e.g. Alzheimer’s disease) [62,65,66]. In some cases, the
involvement of complement is only circumstantial as activated
components have been localized at the sites of clinical disease. In
other cases the involvement of complement was deduced by the
analysis of inhibitors deficiencies in animal models. For example,
the AP is known to be involved in disorders such as ischemia-
reperfusion injury (I/R), systemic lupus erythematosus (SLE),
asthma and rheumatoid arthritis (RA) [72]. In mouse models of
diseases, the fB-/- genotype is associated with no or reduced
alterations (e.g. reduced deposition of C3b in kidney I/R injury)
[73] confirming the role of AP and C3 convertase.
IxAC molecules may have a positive clinical effect in conditions
where inappropriate complement activation involves the binding of
properdin and C3b. This will lead to a reduced production of pro-
inflammatory molecules, reduced deposition of C3b and reduced cell
lysis due to deposition of the MAC. Again, in most complement-
related disorders, the relative contribution of the AP and CP is not
known. More information about these diseases is needed before
IxAC can be used as candidate therapy. Therefore on the one hand,
more information about these diseases is needed before the beneficial
effects of IxAC can be evaluated. On the other hand, however, AP-
specific inhibitors could not be restricted to diseases initiated by AP
activation as, in many cases, the alternative pathway loop is triggered
as a secondary effect to amplify the activation, irrespective of the
initial trigger (AP, CP or lectin pathway). A definite indication for a
putative role of IxACs as anticomplement therapy must await tests in
animal models of candidate diseases. This is the subject of ongoing
experiments in the laboratory.
IxACs may also be used as tools to investigate the role of
complement activation in certain diseases. As its causal role is only
suspected and not proved in many of these disorders, a specific
inhibitor of complement activation may be used in animal models
to determine this role. This was recently achieved in knockout
mice deficient in some complement components. More specifically
and interestingly, IxAC may make it possible to distinguish the
respective contributions of the AP and CP in pathophysiological
mechanisms.
Concluding remarks
To summarize, in this study we described five new anticomplement
proteins from the hard tick Ixodes ricinus and we report the first
specific in-depth analysis of a tick multigene family. Our data suggest
that this inventory of anticomplement sequences is complete for the
investigated population. This provided an opportunity to study
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possible gene diversification mechanisms related to the acquisition of
a bloodfeeding lifestyle by hard ticks. Diversifying selection was
shown to operate. Nevertheless, all proteins had very similar
biochemical properties. They all inhibited formation of C3
convertase by specifically binding to properdin. Differences in host
specificity or patterns of expression could not account for sequence
diversity. However, sequence divergence was associated with
antigenic differences. As individual ticks do not express the same
range of anticomplement proteins, certain individuals in a
population would be able to escape the host immune reaction.
This is the first time that inhibition of the alternative pathway
via the specific binding of a positive regulator is described. This is
an efficient way of blocking the innate immune system and
preventing early rejection of the tick by the host. Recombinant
IxACs may therefore be useful tools for the investigation of the role
of properdin in physiological and pathophysiological mechanisms.
Because activation of the alternative complement pathway is
involved in major human diseases such as ischemia-reperfusion
injury, systemic lupus erythematosus (SLE), asthma and rheuma-
toid arthritis (RA), AP inhibitors may prove to be therapeutically
beneficial [72]. To date, only two complement inhibitors have
reached the pre-clinical testing stage: recombinant soluble
complement receptor 1 (sCR1) [74] and anti-C5 monoclonal
antibodies [75]. However, they do not act specifically on AP [19].
Selective inhibition of the AP by properdin inhibitors such as
IxACs may therefore be used to treat pathological effects of
uncontrolled complement activation by this pathway, without
compromising the classical and lectin pathways.
MATERIALS AND METHODS
Tick material
Specimens of Ixodes ricinus were raised in the tick breeding facility at
the Institut de Zoologie, Universite´ de Neuchaˆtel (Switzerland). Founders of
the colony were initially collected in woodlands near Neuchaˆtel and
have been maintained on rabbits (adults and nymphs) and SWISS
mice (larvae) for over 20 years. Specimens of Rhipicephalus appendi-
culatus strain Mugaga were a kind gift of Dr Maxime Madder
(Animal Health department, Prince Leopold Institute of Tropical
Medicine, Antwerp, Belgium). The colony originated from individ-
uals collected in East Africa. It was routinely maintained on rabbits.
All specimens were devoid of transmissible pathogens.
Pairs of salivary glands from I. ricinus were dissected from i) 70
adult female specimens at day 5 of the bloodmeal; ii) 25 females at
day 3 of the bloodmeal, iii) 25 unfed females, iv) 10 individual
females at day 5 of the bloodmeal. Pools of 25 fully gorged larvae
and 25 fully gorged nymphs were also prepared. In addition,
salivary glands were prepared from 25 adult female and 25 adult
male R. appendiculatus.
Nucleic acid extraction and analysis
PolyA+ RNA was extracted from tick material using the Micro-
Fasttrack 2.0 (Invitrogen).
All polyA+ RNA were reverse transcribed with Superscript III
(Invitrogen) in the presence of RNaseOUT ribonuclease inhibitor
(Invitrogen) using Not1-d(T)18 bifunctional primer (Amersham
Biosciences). PolyA+ RNA from pooled day 5 salivary glands was
also reverse transcribed with Superscript II (Invitrogen) using the
GeneRacer oligodT reverse transcription primer (Invitrogen).
59 and 39 RACE experiments were performed using the
Generacer kit (Invitrogen).
For restriction analysis, sequencing and small-scale transfection
experiments, recombinant plasmid DNA was extracted using
Genelute Plasmid Miniprep Kit (Sigma).
Plasmid constructs were sequenced using universal sequencing
primers at Biovalle´e A.S.B.L. (Gosselies, Belgium) and at Genome
Express (Meylan, France).
All commercial reagents and kits were used according to the
manufacturers’ instructions.
RT/PCR inventories of IxAC sequences in I. ricinus
PolyA+ RNA extracted from 70 pooled pairs of salivary glands
from I. ricinus females on day 5 of the bloodmeal was reverse
transcribed using two different sets of reverse transcriptase and
oligodT primers. cDNA1 was generated with Superscript II using
the GeneRacer oligodT reverse transcription primer (Invitrogen).
cDNA2 was produced with Superscript III (Invitrogen) in the
presence of RNaseOUT ribonuclease inhibitor (Invitrogen) using
Not1-d(T)18 bifunctional primer (Amersham Biosciences). Both
were used for RT/PCR experiments designed to make an
inventory of the family of anticomplement proteins in I. ricinus.
Upstream primers were designed manually from the 59 end of
coding sequences of anticomplement proteins available early in
this project from I. ricinus (IRAC I and II, AM407396, AM407397:
IRI primer) or from all available Ixodes spp. sequences (IRAC I and
II, AM407396, AM407397, ISAC, Isac-1: IXO primer). Commer-
cial downstream primers Generacer 39 (Invitrogen) and Not1
(Amersham Biosciences) are designed to anneal to the 59 end of
the modified oligodT primers used for reverse transcription. In
addition, downstream primers UTR1 and UTR2 were designed
from the 39 UTR of anticomplement sequences. All primers are
listed in Table 1. They were purchased from Eurogentec (Lie`ge,
Belgium) and diluted to 10 mM in MillliQ water.
Six primer pairs were thus constituted: i) IRI-generacer39, ii) IXO-
generacer39, iii) IRI-Not1, iv) IXO-Not1, v) IXO-UTR1, vi) IXO-UTR2.
Primer pairs (i) and ii) were used on cDNA1 whereas primer pairs
(iii) to (vi) were used on cDNA2 (Table S1). PCR amplification
experiments were performed with the Expand High Fidelity Plus
PCR System (Roche) in a final volume of 50 ml of commercial
buffer containing 1.5 mM MgCl2. PCR cycling parameters were
as follows: 2 min denaturation at 94uC, then 30 cycles of 30 sec at
94uC, 30 sec annealing at 61 to 65uC (depending on the Tm of the
primer pairs), 1 min at 72uC, then final incubation for 7 min at
72uC in a PTC-100 Programmable Thermal Controller (MJ
Research). Annealing temperature was set at the lower Tm for a
given primer pair minus 5uC.
PCR products were routinely purified on polyacrylamide gels
and inserted into both the pCRII and the pCDNA3.1/V5-His
vectors (Invitrogen) by the TA method. Top10F’ chemically
competent E. coli cells (Invitrogen) were then transformed and
plated onto LB-Agar-Ampicillin solid medium. Plasmid DNA
from recombinant clones was analysed by EcoRI (pCRII) or
BamH1–Xba1 (pcDNA3.1/V5-His-TOPO) restriction and inserts
$600 bp were sequenced on both strands.
Therefore a total of 2 different reverse transcription experi-
ments, 6 different PCR amplifications and 12 ligations were
performed during the course of RT/PCR inventories of
anticomplement sequences in salivary glands of I. ricinus females.
RT-PCR analysis of expression of individual IxACs
Pairs of PCR primers (Table S3) were designed from an alignment
of the I. ricinus IxAC coding sequences to specifically amplify each
of the family members one at a time, each primer pair generating
a product of different size. They were synthesized by Sigma-
Genosys and purified by HPLC. The specific messengers were
searched by RT/PCR in polyA+ prepared from i) salivary glands
of individual adult females at day 5 of the bloodmeal, ii) pooled
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salivary glands at day 0 of the bloodmeal (unfed females), iii)
pooled salivary glands of females at day 3 of the bloodmeal, iv)
pooled nymphs and v) pooled larvae.
PCR was performed using Taq polymerase in a 50 ml reaction
volume according to the manufacturer’s instructions (Roche
Biochemicals). Except for IxAC-B4, PCR cycling conditions were
as follows: 2 min denaturation at 94uC then 40 cycles of 30 sec at
94uC, 30 sec annealing at 57uC, 30 sec elongation at 72uC
followed by a final 7 min. elongation at 72uC on PTC-100. This
set of PCR conditions had to be slightly modified to amplify the
specific IxAC-B4 fragment: 45 cycles and annealing at 60uC.
PolyA+ submitted to reverse transcription without the actual RT
enzyme were used as negative control template.
In parallel, family-specific reverse primers were designed from
UTR or coding sequences to amplify the full coding sequences of
members of IxAC-A (IXO-CDSREV1) and IxAC-B (IXO-
CDSREV2) (Table 1). They were applied to cDNA from pooled
nymphs and pooled larvae using the Expand-HF+ system for PCR
amplification as described above.
Expression and quantification of recombinant
proteins
The coding sequences for I. ricinus IxACS were amplified by PCR
and inserted into the vector pCDNA3.1/V5-His-TOPO (Invitro-
gen). Upstream primers were designed from the first 20 nt of each
coding sequences. Nucleotides surrounding the ATG were
changed to ACCATGG (IRAC I, IxAC-B1 to B5) or GCCATG
(IRAC II) according to Kozak’s consensus for efficient initiation of
translation [76]. Downstream primers were designed from the 39
end of the coding sequences omitting the TGA stop codon so as to
create IxAC-V5His chimeras.
The coding sequence for Rhipicephalus appendiculatus histamine-
binding protein 2 (RaHBP2) was also amplified from salivary
gland cDNA of adult R. appendiculatus females using PCR primers
designed from the original published sequence (U96081) [77] and
inserted into vector pCDNA3.1V5His. Throughout this study,
recombinant RaHBP2 was used as a negative control.
Subconfluent 293T cells in 35 mm diameter wells (Orange
Scientific) were transfected with 2 mg plasmid DNA and 6.0 ml
Fugene 6 (Roche Biochemicals) in Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen) without FCS. The medium was
harvested after 72h. Pooled supernatants were cleared by
centrifugation, concentrated ,50-fold by filtration on 30 kDa
cut-off membranes (Millipore), dialyzed against GVB or VB
buffers, and finally stored at –80uC in 40 ml aliquots.
Concentrated culture supernatants were analyzed by western
blotting on a Hybond ECL membrane (GE healthcare) using an
anti-V5 primary antibody (Invitrogen), an IgHRP conjugate as
secondary antibody and the ECL detection reagent (GE healthcare)
following the manufacturer’s instructions. Autoradiogram signals
were quantified with ImageQuant TL Software (GE Healthcare).
The relative amounts of protein were adjusted by diluting the most
concentrated IxAC protein to the level of the less concentrated one.
After normalization, new western blot analyses showed not more
than 2.5-fold differences in protein concentrations.
Samples were also subjected to N-deglycosylation using N-
glycosidase F (New England Biolabs) using conditions recom-
mended by the manufacturer.
The coding regions of IRAC II and IxAC-B1 were amplified by
PCR (94uC for 30 s, 56uC for 30 s, 72uC for 1 min.; 30 cycles)
using ExTaq DNA Polymerase (Taqara). The PCR product was
inserted into the pBlueBac4.5/V5-His Topo vector (Invitrogen) in
frame with the coding sequence of the V5 and His epitopes at the
C-terminus. Recombinant baculoviruses were generated by
recombination between pBlueBac/IxAC and Bac-N-Blue linear
DNA virus (Invitrogen). Recombinant viruses were selected and
amplified according to the manufacturer’s instruction. Sf9 cells
were infected with a high-titer stock of recombinant baculovirus
and were incubated for 72 hours at 27uC in Sf900 II serum-free
medium (Invitrogen). Recombinant IxACs proteins were purified
from the cell culture supernatant by affinity chromatography on a
His-Trap column (GE Healthcare). The proteins were recovered
in 50 mM NaH2PO4 buffer (pH 7.5) containing 300 mM NaCl
and 50 mM of imidazole. In experiments with purified proteins,
we used protein Iris, a serpin from the salivary gland of I. ricinus
[78], as a negative control because it was also expressed in the
baculovirus/Sf9 and purified in the same manner.
Computer-assisted analysis of sequences and
database interrogations
Probable cellular targeting and eukaryotic leader peptide cleavage
site were identified in amino-acid sequences with the Target P and
Signal P programs respectively [79]. N-linked glycosylation and
O-GalNAc (mucin type) glycosylation sites were predicted with the
NetNGlyc 1.0 and NetOGlyc 3.1 [80] programs respectively. An
hydrophobic anchor at the C-terminal end of the peptide sequence
was searched for with the TMHMM v. 2.0 [81] program that
predicts transmembrane helices in proteins. All were used online at
the Center for Biological Analysis of the Technical University of
Denmark (CBS prediction servers: http://www.cbs.dtu.dk/
services/). Calculation of molecular weight and isoelectric point
were performed with the Pepstats program from EMBOSS online
at the European Bioinformatics Institute (http://www.ebi.ac.uk/
emboss/pepinfo/). Putative S-S links were searched with program
Disulfind [82] at http://cassandra.dsi.unifi.it/disulfind/.
Tick anticomplement amino-acid sequences were submitted to
Hydrophobic Cluster Analysis (HCA) [83,84]. Briefly, amino-acid
sequences in an alignment are compared for the overall
distribution of hydrophobic clusters, their sizes, shapes and
orientations. They can also be compared for possible particular
structures induced by specific residues.
The non-redundant, EST, GSS and PDB databases were
interrogated online at the NCBI server (http://www.ncbi.nlm.nih.
gov/BLAST/) using Blast family programs. Nucleotide and amino
acid sequences of ISAC, IRAC I, IxAC-B1 were used as queries.
We also interrogated the preliminary releases of the genome
projects for non-Ixodes hard ticks Amblyomma variegatum, Boophilus
microplus, Rhipicephalus appendiculatus online at the Institute for
Genomic Research (http://tigrblast.tigr.org/tgi) and A. americanum
available at the University of Oklahoma cDNA Blast Server
(http://www.genome.ou.edu/tick.html).
Phylogenetic analysis
Coding sequences were aligned using ClustalW under the Mega3
package to obtain inframe alignment of codons. Minor manual
adjustments were made at the 39 end (C-terminus) of the
alignment. The Genedoc package [85](http://www.psc.edu/
biomed/genedoc/) was used to visualize alignments and calculate
percent identity of nucleotide and peptide sequences. Percent
similarity of peptide sequences was also calculated with Genedoc
using a Blosum 62 matrix. For phylogenetic analysis by the
distance methods, we used programs in the Phylip 3.65 package
(http://evolution.gs.washington.edu/phylip.html). The substitu-
tion model was F84 for nucleotide sequences and the JTT matrix
for amino-acid sequences distance analysis. The PHYML 2.4.4
package [86] (http://atgc.lirmm.fr/phyml/) was used for maxi-
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mum likelihood analysis. We used the HKY model for nucleotide
sequence analysis and the JTT model for amino-acid sequences
analysis. Transition to transversion ratios and proportions of
invariable sites were estimated from the dataset. No c distribution
of rates among sites was applied. Bootstrap analysis was performed
on 1000 replicates of the initial datasets. Trees were visualized
with Treeview 1.6.6 [87]. Phylogenetic analyses were repeated on
amino-acid and nucleotide alignments with or without the leader
peptide sequences.
We used the Ancescon package to reconstruct a probable
ancestral coding sequence [88] (http://protevo.eb.tuebingen.mpg.
de/toolkit/index.php?view = ancescon) from an alignment of the
coding sequences for I. ricinus IxAC mature proteins. The dN and
dS values were calculated using the Nei-Gojobori method as
implemented in the MEGA 3.1 package [89] (http://www.
megasoftware.net/).
Serum samples
Complement assays were conducted with freshly prepared sera
from the mammals, birds and squamates (snakes and lizards) listed
in Table 5. All animals were healthy and non-immunized. Except
for red deer, they had been maintained in confined environments
and there was no evidence or history of tick bites.
Fresh blood samples were left to clot at room temperature for 2
to 6 hours. The sera were separated from the clot by centrifuga-
tion. They were then aliquoted and stored at –80uC. Hemolysed
samples were discarded.
Human sera were obtained from four healthy male volunteers,
Beagle dog (Canis familiaris) sera from three individuals, sheep (Ovis
aries) sera from five individuals, pig (Sus domesticus) sera from two
individuals, calf (Bos taurus) sera from three individuals, deer (Cervus
elaphus scoticus) sera from three individuals. Ten female Balb/c
mice (Mus musculus) purchased from Harlan Netherlands were bled
by retro-orbital puncture. Chicken (Gallus gallus) sera were
obtained and pooled from four individuals, pheasant (Phasianus
colchicus) sera from five birds, domestic turkey (Meleagris gallopavo)
serum from one individual, pigeon (Columba liva) sera from five
individuals, lizard (Tropidurus torquatus) sera from two individuals,
snake sera from one individual (Boa constrictor) and three individuals
(Elaph guttata).
Assay of the alternative complement pathway (AP)
Recombinant proteins were assessed for their capacity to inhibit
the alternative complement pathway (AP) according to Giclas [90]
on red blood cells (RBC) from naı¨ve healthy female New Zealand
White rabbits. Briefly, fresh sera were diluted in gelatin-veronal-
EGTA buffer (GVB) in microwell plates and washed RBCs were
added. The surface of rabbit erythrocytes activated the alternative
complement pathway leading to their lysis and release of
hemoglobin in the buffer. After 60 min incubation at 37uC,
supernatants were recovered to measure absorbance at 415 nm
with a Model 680 microplate reader (Biorad). The volume of
serum causing 50% hemolysis (AH50 value) was then determined
by serial dilutions and used for further tests.
1 to 10 ml of serum were introduced in the test depending of the
host species considered. 100% lysis control consisted in total
hemolysis produced by incubating 25 ml of MilliQ water.
Background level (no hemolysis) was determined by incubating
the erythrocytes in GVB buffer alone (without added serum). Each
experimental point was done in triplicate and experiments were
performed at least twice, by different investigators.
In order to test the inhibitory effect of the new proteins, up to
10 ml of standardized supernatant (see above) were introduced in
the AP test. The inhibitor was serially diluted in a final volume of
25 ml GVB in the presence of AH 50 volumes of the host serum
under consideration. The assay was then performed as described
above. Percent inhibition of hemolysis was then calculated with
the equation:
1(OD415nm serumzinhibitor½ OD415nm GVB control)
h i
|100
OD415nm serum only½ OD415nm GVB controlð Þ:
The kinetics of hemolysis inhibition were also investigated. The
hemolytic AP assay was conducted as described above except that
we added 200 ng of purified recombinant IRAC II, IxAC-B1 or
unrelated protein IRIS to wells 10 minutes after the addition of
RBC. Optical density at 415 nm was then taken every 5 or
10 minutes.
Assay of the classical pathway (CP)
Recombinant proteins were also tested for inhibition of the
classical complement pathway (CP) essentially as described by
Colligan [91]. Ready-to-use reagents were purchased from Institut
Virion\Serion GmbH (Wu¨rtzburg, Germany). They included
sheep erythrocytes pre-coated with rabbit anti-sheep RBC
antibodies and Veronal Buffer pH 7.3 (VB) containing NaCl,
CaCl2 and MgCl2. Briefly, diluted serum was incubated in the
presence of antibody-coated sheep RBCs in microplates. Immune
complexes on the surface of RBCs activate the classical pathway of
complement leading to lysis and release of hemoglobin. As in the
AP assay, absorbance at 415 nm in the supernatant is proportional
to the amount of lysed RBC. Pooled human serum was first
titrated to determine the volume that produces 50 % hemolysis
(CH50 value). Starting with 10 ml, standardized amounts of
recombinant proteins were diluted two-fold in VB buffer
containing the equivalent of 0.8 ml human serum per test (total
volume 25 ml). Pre-coated sheep erythrocytes were then added and
the reaction performed as described above. Results were expressed
as percent inhibition of hemolysis as for the AP pathway.
Western blot analysis of fB cleavage and C3a
formation in the AP assay
The generation of peptide C3a from C3 and the cleavage of factor
B in human serum during the AP assay in the presence of I. ricinus
IxACs were assessed by western blot analysis as described by
Lawrie et al. [39]. 10 ml of supernatant from AP assays conducted
in the presence of I. ricinus IxAC or control protein RaHBP2 were
analyzed by denaturing SDS/PAGE (C3 cleavage) or by non-
denaturating PAGE (fB cleavage). Purified factor B was also
included as a control in the analysis. Briefly, 10% acrylamide
SDS/PAGE in tris–tricine buffer were run according to standard
methodology. 10% acrylamide non-denaturating gel electropho-
resis was conducted as described except that SDS and b-
mercaptoethanol were omitted in all buffers. The material was
blotted onto nitrocellulose sheets according to standard method-
ology. Rabbit anti-human C3a serum (Calbiochem, dilution
1:5000) or goat anti-human factor B serum (Quidel, dilution
1:1000) were used as primary antibodies. Anti-rabbit IgG or Anti-
goat IgG horseradish peroxidase conjugates (Promega, dilution
1:5000) were used as secondary antibodies. Blots were developed
using the chemiluminescence substrate, ECL+ kit from Amersham
(Bucks, UK) according to the manufacturer’s instructions.
Membranes were then exposed to KODAK X-ray film.
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Enzyme-linked Immunosorbent assay for measuring
the binding of recombinant IxAC to components of
C3 convertase
The binding of the seven recombinant I. ricinus IxAC proteins and
control protein RaHBP2 to components of human C3 convertase
was assessed using an enzyme-linked immunosorbent assay
(ELISA). In some experiments, we also used recombinant IRAC
II, IxAC-B1 and control protein Iris purified from the Baculo-
virus/Sf9 expression system.
Wells in 96-well polystyrene microtiter plates (Nunc) were
coated with 200 ng of purified C3, C3b, factor B, factor D or
properdin (Calbiochem) in 100 ml pH 7.4 phosphate-buffered
saline (PBS, Invitrogen) overnight at 4uC. Wells were washed three
times for 5 min. with washing buffer (8.1 mM Na2HPO4; 1.8 mM
NAH2PO4; 0.05% Tween 20; 25 mM NaCl; 10 mM MgCl2) and
blocked with PBS-Tween-BSA buffer (1% BSA, 0.1 % Tween 20
in PBS pH 7.4) for 1h at 37uC. Increasing amounts of
recombinant I. ricinus IxACs and control proteins in 50 ml sample
buffer (8.1 mM Na2HPO4; 1.8 mM NAH2PO4; 4% BSA; 0.05%
Tween 20; 75 mM NaCl; 10 mM MgCl2) were added to the wells.
After incubating for 1 h at 37uC, wells were washed 3 times with
washing buffer. 100 ml antibody buffer (8.1 mM Na2HPO4;
1.8 mM NAH2PO4; 4% BSA; 0.05% Tween 20; 25 mM NaCl;
10 mM MgCl2) containing a mouse anti-V5 antibody (Invitrogen,
dilution 1:5000) were added to the wells. Plates were incubated for
1h at 37uC then washed again three times. Horseradish
peroxidase-conjugated anti-mouse IgG antibodies (Promega,
diluted 1:7500) in 100 ml antibody buffer were incubated for 1h
at 37uC. After 3 washes, 50 ml of 3,39,5,59 –Tetramethylbenzidine
(TMB, Sigma) substrate was added. The reaction was stopped by
adding 50 ml H2SO4 0.2 N. Optical density at 450 and 630 nm
was measured with a Model 680 microplate reader (Biorad). In a
first series of experiments we tested the binding of purified
recombinant IRAC II and IxAC-B1 and unrelated protein IRIS to
C3 convertase components. In the second series we tested
standardized amounts of the 7 I. ricinus IxAC and control protein
RaHBP2 as expressed in the supernatant of transfected 293T cells
(see above) on purified properdin alone.
We also assessed the effect of recombinant IRAC II, IxAC-B1
and unrelated protein IRIS on the binding of Properdin to C3b.
Wells were coated with 150 ng of C3b. 200 ng factor P and
increasing concentrations of IRAC II, IxAC-B1 or unrelated
protein IRIS in sample buffer were added simultaneously to the
wells. The amount of bound properdin was estimated using a
primary mouse monoclonal antibody to factor P (diluted 1:2000;
Quidel) and horseradish peroxidase-conjugated anti-mouse IgG
antibodies (diluted 1:7500; Promega) using the above-described
ELISA method.
Enzyme-linked immunosorbent assays for assessing
the effect of IxACs on the formation and stability of
C3 convertase
We assessed the effect of recombinant IxAC proteins on the
formation and stability of C3 convertase in vitro using the above-
described ELISA method. 96-well polystyrene microtiter plates
were first coated with 150 ng of C3b per well. The effect of IxAC
proteins on the formation of C3 convertase was assessed by adding
200 ng of factor B, 20 ng of factor D, 200 ng of factor P in sample
buffer to the wells together with increasing concentrations of
IRAC II, IxAC-B1 or Iris. Plates were incubated for one hour at
37uC before antibody detection of fB or P. To assess the effect of
IxACs on the stability of the C3 convertase, C3b-coated wells were
incubated for 1 h with 200 ng of factor B, 20 ng of factor D,
200 ng of factor P in sample buffer. The wells were washed three
times before deposition of IRAC II, IxAC-B1 or IRIS proteins.
The plates were further incubated for one hour at 37uC. Anti-
factor P (dilution 1:2000) and anti-factor B (dilution 1:1000) were
used as primary antibody to detect bound proteins as described
above. Results are expressed as % bound fB or properdin using the
following formula:
1(OD maxOD background) (OD sampleOD background)
h i
|100 (OD maxOD background):
Background values were obtained by measuring OD values of
C3-coated plates revealed with anti-fB or anti-properdin antibod-
ies. OD max was measured by performing the test without added
IxAC.
In a complementary experiment, we compared the effect of
IRAC I, IxAC-B1 and the control protein Iris on the formation of
C3 convertase in the presence (C3bBbP) or absence of properdin
(C3Bb). 200ng of factor B, 20 ng of D, with or without 20 ng of
properdin, and 200 ng of IRAC I, IxAC-B1 or control protein Iris
were added to microtiter wells pre-coated with 150 ng purified
C3b. The reaction was stopped at 0, 20, 40 and 60 min. and
bound factor B or properdin were detected with the respective
specific antibodies using the above-described ELISA method.
Enzyme –linked immunosorbent assays for
measuring C3 and factor B deposition on agarose-
coated wells
The ability of I. ricinus IxACs to alter AP activation by a solid phase
was assessed by agarose ELISA as described by Valenzuela et al. [25]
with minor modifications. Deposition of C3b and fB on agarose-
coated microplates was used to measure AP activation and C3
convertase formation. Briefly, wells of polystyrene microplates
(Nunc) were coated with 100 ml of 0.1% melted agarose in water
and incubated at 37uC for 48 h. Wells were then incubated with
50 ml of 200 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM EGTA,
2 mM MgCl2, and 10% human serum for 90 min at 37uC. After 30,
45 or 60 minutes, 200 ng of purified IRAC II or IxAC-B1 was
added to the plates. The reaction was stopped by washing five times
with 200 ml of HEPES saline containing 2 mM MgCl2 and 10 mg/
ml bovine serum albumin (HEPES-BSA buffer). Bound C3b and fB
were revealed by Elisa. Goat anti-human C3 serum (Quidel, diluted
1:5000) or goat anti-human fB serum (Quidel, diluted 1:1000) used
as primary antibodies were incubated for 1 h at 37uC in HEPES-
BSA buffer. Wells were washed 5 times with 200 ml HEPES-BSA
and IgG anti-goat peroxidase-conjugate (Promega, diluted 1:5000)
was then added as secondary antibody and incubated for 1 h at 37uC
in HEPES-BSA. Plates were washed twice with HEPES-BSA, then
twice with HEPES containing 10% Tween 20, and finally twice with
HEPES buffer alone. 50 ml of 3,39,5,59 –Tetramethylbenzidine
substrate (TMB, Sigma) was then added to each well and the
developed color reactions were stopped by adding 50 ml 0.2 M
H2SO4. Optical density at 450 and 630 nm was measured with a
Model 680 microplate reader (Biorad).
Immunization and antigen assay
IxAC-B1-specific antibodies were produced in Balb/c mice by
DNA immunization followed by a booster protein injection.
Briefly, 100 mg of plasmid pCDNA3.1/IxAC-B1_V5-His DNA in
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saline was injected four times in the anterior tibialis at three week
intervals. Animals were then boosted once with 1 mg purified
IxAC-B1 in Alum (Brenntag Biosector, DK). Sera were taken by
retro-orbital puncture two to 5 weeks after the booster injection.
Recombinant IxAC-B1_V5His protein was produced by trans-
fecting subconfluent 293T cells with plasmid pCDNA3.1/IxAC-
B1V5His in serum-free culture medium. The recombinant protein
was purified from cell culture supernatants by chromatography on
NiNTa columns (Invitrogen). Pre-immune and immune antisera
were tested by western blot on the 7 I. ricinus IxACs and assessed in
vitro for neutralization of anticomplement activity in the AP test.
We reasoned that if seroneutralization occurred, antibodies would
block inhibition of AP by IxACS and hemolysis would occur.
3.0 ml heat-inactivated mouse antisera were preincubated for
30 min at room temperature with 2.0 ml samples of standardized
IxACS. The mixture was then added to 2.0 ml human serum in
GVB buffer in a total volume of 25 ml. 25 ml RBC were then
added and the AP assay was conducted as described above.
Controls included i) sera from mice previously mock-immunized 3
times with PBS in Freund’s adjuvant, ii) serum from mice
immunized with the unrelated protein Iris [78], iii) GVB buffer.
Results are expressed as % hemolysis as:
(OD415 sampleOD415 GVB)|100
(OD415 serumOD415 GVB)
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